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Introduction 

Introduction 
Although erythropoietin (EPO) is not the sole growth factor responsible for 
erythropoiesis, it is the most important factor in the regulation of red blood cell 
formation. It is the only haematopoietic growth factor that behaves like a hormone. 
EPO is mainly produced in the kidneys, and through control of its production the 
kidneys are the main regulatory organs of erythropoiesis and, therefore, essential for 
tissue oxygenation. Consequently, hypoproliferative anaemia is almost invariably a 
concomitant feature of chronic renal failure, resulting mainly from insufficient EPO 
production. The development of recombinant DNA technology and cloning of the EPO 
gene in 1985, provided tools to obtain sufficient quantities of recombinant human 
erythropoietin (r-HuEPO, epoetin) for application as a rational substitution therapy in 
patients with anaemia of chronic renal failure. R-HuEPO is indistinguishable from 
endogenous EPO by immunological or biological techniques. 
From 1987, patients with anaemia of end-stage renal failure who were not yet on 
dialysis were treated with r-HuEPO. The results of our first clinical experiences are 
described in chapter 1. However, based on theoretical considerations and results from 
animal studies, objections were raised against the use of r-HuEPO in pre-dialysis 
patients. The increase in haematocrit might adversely affect renal function and so 
accelerate the rate of progression of renal failure. Further studies of renal function and 
renal haemodynamics before and during treatment with r-HuEPO are described in 
chapter 2. Studies addressing these issues, and potential problems concerning studies 
of renal function during treatment with r-HuEPO are more comprehensively reviewed 
in chapter 3. Patients treated with continuous ambulatory peritoneal dialysis were the 
last group to benefit from r-HuEPO. A feasibility study designed to establish the 
efficacy and safety of r-HuEPO after intraperitoneal administration compared to 
subcutaneous administration in these patients is described in chapter 4. There are 
currently different r-HuEPO products being used and investigated. Epoetin alpha and 
epoetin beta are r-HuEPO products from two independent manufacturers, and they 
differ only slightly as regards pharmacokinetics. However, we observed that 
subcutaneous administration of the epoetin alpha formulation often caused pain at the 
injection site, sometimes precluding self-administration. The two products were 
directly compared in a study assessing their local tolerance, which is described in 
chapter 5. In chapter 6 we describe a clinical study of the component parts of the 
epoetin alpha formulation, to reveal the substance that causes pain. Potential measures 
to reduce local pain after subcutaneous administration of epoetin alpha are described 
in chapter 7. Rapid and enthusiastic clinical introduction of r-HuEPO as a proven and 
beneficial treatment for the anaemia of chronic renal failure preceded the initiation of 
more fundamental studies. There exist only few pharmacodynamic data pertinent to 
r-HuEPO, and the pharmacokinetic data for r-HuEPO indicate neither a rational basis 
for therapeutic serum levels nor its optimal pharmacokinetic profile. Dosage 
recommendations for r-HuEPO are, therefore, still largely empirical. With regard to 
the different routes of administration of r-HuEPO, relevant facts are reviewed in 
chapter 8. 
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CHAPTER 1 
Efficacy and Tolerance of Treatment 
with Recombinant Human Erythropoietin 
in Chronic Renal Failure (Pre-Dialysis) Patients 
L.A.M. Frenken*, R. Verberckmoest, P. Michielsenf, and R.A.P. Koene* 
From the Department of Medicine, Division of Nephrology, *University Hospital 
St. Radboud, Nijmegen, The Netherlands, and fUniversity Hospital Gasthuisberg, 
Leuven, Belgium. 
Published in: Nephrology Dialysis Transplantation. 1989;4:782-786. 
Abstract 
• Objective: To determine the efficacy and tolerance of treatment wi th 
recombinant human erythropoietin (r-HuEPO) in chronic renal failure (pre-dialysis) 
patients. 
• Design: Prospective analysis of an open, randomised dose investigation. 
• Setting: Outpatient clinics of two university hospitals. 
• Patients: Twenty-four pre-dialysis patients with anaemia of end-stage renal 
failure. 
• Intervention: R-HuEPO was injected intravenously three times a week during the 
first two months (correction phase). Fixed dosages of 50 U/kg, 100 U/kg, and 150 
U/kg were used, and each dose group consisted of eight patients. During the 
subsequent six months r-HuEPO was given once a week and the dosages were 
adjusted to maintain a stable haemoglobin value (maintenance phase). 
• Main outcome measures: Efficacy was assessed by measuring the increase in 
haemoglobin. Tolerance was assessed by monitoring side effects. 
• Results: The mean ± SD haemoglobin increased from 5.8 ± 0.4 to 6.9 ± 0.8 
mmol/L wi th 50 U/kg, from 4.9 ± 0.9 to 7.3 ± 1.1 mmol/L wi th 100 U/kg, and 
from 5.2 ± 0.6 to 7.5 ± 0.7 mmol/L with 150 U/kg of r-HuEPO. The two highest 
dose groups showed a marked reticulocytosis and a transient thrombocytosis. 
During the maintenance phase haemoglobin levels remained stable (7.4 ± 0.7 
mmol/L) at a mean dose of 199 ± 139 U/kg of r-HuEPO per week. Blood pressure 
did not increase, but in nine of eighteen previously hypertensive patients 
antihypertensive medication was increased. In one hypertensive patient seizures 
developed. No accelerated progression of renal failure could be demonstrated. All 
patients reported an improved sense of well-being. 
• Conclusion: Recombinant human erythropoietin is a safe and effective agent for 
the treatment of anaemia of end-stage renal failure in pre-dialysis patients. 
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In most patients with chronic renal failure anaemia is an important concomitant 
feature. The severity of anaemia increases during the progression of chronic renal 
failure to end-stage renal disease. Recently it was shown that administration of 
recombinant human erythropoietin (r-HuEPO) is an effective treatment for the anaemia 
of end-stage renal disease in haemodialysis patients (1, 2). Adverse effects have 
included hypertension, hypertensive encephalopathy with seizures, and thrombosis in 
arterio-venous fistulae. The precise relationship of r-HuEPO to these events is unclear. 
They may be related to the increased red cell volume induced by r-HuEPO treatment, 
or to the rate of increase in haemoglobin. 
Experience with r-HuEPO in pre-dialysis patients is still limited. There is one study 
in 12 pre-dialysis patients demonstrating a satisfactory haematological response (3). 
It is thus likely that these patients will also respond to r-HuEPO. However, their 
sensitivity and in particular their susceptibility to the above-mentioned side-effects are 
largely unknown. In addition, the study of these patients merits special attention since 
the rate of decline in renal function may be influenced by the treatment. In a phase II 
clinical trial we have, therefore, investigated the safety and efficacy of r-HuEPO 
treatment in pre-dialysis patients with chronic renal failure during correction of the 
anaemia and during maintenance therapy. 
Patients and Methods 
Patients 
Twenty-four patients were included in the trial: 13 females and 11 males, aged 23 
to 68 years. They all had a known history of progressive chronic renal failure whereas 
other clinically significant diseases were absent. Serum creatinine ranged from 375 to 
1304 μτηοΙ/L. All patients were anaemic with haemoglobin ranging from 3.3 to 6.3 
mmol/L and haematocrit from 0.16 to 0.30 L/L. The anaemia could not be attributed 
to other causes. None of the patients had experienced an acute illness within seven 
days or had received blood transfusions within 30 days of the start of the study. 
Hypertension was either absent or medically controlled. The underlying renal diseases 
were: chronic pyelonephritis in five, glomerulonephritis in five, polycystic kidney 
disease in four, analgesics abuse in three, reflux nephropathy in two, congenital 
solitary kidney in one, congenital hypoplastic kidneys in one, focal glomerulosclerosis 
in one, and unknown renal disease in two patients. The patients received stable doses 
of oral iron supplementation (up to 200 mg of elemental iron per day) and folic acid 
for two weeks prior to inclusion in, and for the duration of, the study. Dietary and 
medication regimens were stable for at least one month before study entry and 
attempts were made to keep them constant. 
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Methods 
All patients gave written informed consent. The study protocol was approved by the 
local Hospital Ethics Committees of the participating institutions. The protocol was 
divided into two therapeutic periods: a phase of correction of the anaemia and a 
maintenance phase. At the start of the correction phase the patients were randomly 
assigned to three dosage groups each containing eight patients. The doses were 50, 
100 and 150 units of r-HuEPO per kilogram of body weight (U/kg) per injection. 
After a two-week period of base-line measurements the patients were given 
intravenous injections of r-HuEPO three times a week for eight weeks. At the 
completion of this eight-week study, or whenever a patient's haematocrit exceeded the 
target values (0.37 L/L for female, 0.39 L/L for male) by two percentage points, the 
patient was entered into the maintenance study. During the maintenance phase 
r-HuEPO was injected intravenously once a week. The starting dose was three times 
the dose given per injection during the correction phase, adjusted for response. Dose 
adjustments were made at least every four weeks. The dose of r-HuEPO was increased 
or decreased in steps of 75 U/kg per week to maintain the haematocrit close to the 
target value. When the haematocrit exceeded 0.40 L/L, the administration of r-HuEPO 
was stopped until the haematocrit had decreased to below the target value. When a 
rapid increase in blood pressure occurred, no r-HuEPO was given until blood pressure 
was under control. For safety reasons the target value for haematocrit was reduced in 
October 1987 to 0.35 L/L for both females and males, taking into account the Adverse 
Event Reports from other r-HuEPO studies. 
Haemoglobin, haematocrit, and blood cell counts were done twice weekly in the 
correction phase and at least once monthly in the maintenance phase. Routine serum 
chemistry was monitored once a week during the correction phase and once monthly 
later on. Blood pressure (supine, before venepuncture) was monitored before each 
dosing. The serum creatinine values of the individual patients during the two years 
preceding the study were retrieved from the clinical records. Mean arterial pressure 
(MAP) was calculated as diastolic pressure plus one-third of the pulse pressure. The 
numbers of antihypertensive drugs prescribed before therapy were recorded as units 
of antihypertensive medication. Every adjustment of dose or number of anti­
hypertensive drugs was recorded as an increase or decrease in the number of units of 
antihypertensive medication prescribed. 
The reciprocal of serum creatinine can be used to estimate the rate of deterioration 
of the glomerular filtration rate (4). We used the equivalent 1000 divided by serum 
creatinine (μπιοΙ/L) to calculate this rate. When sufficient values of serum creatinine 
recorded before therapy were available, linear regression by least squares was applied 
to the reciprocal of serum creatinine versus time data. 
Differences from base-line values within groups were evaluated using the two-tailed 
Student /-test for paired data. The slopes of the regression lines obtained before and 
after the start of r-HuEPO therapy were compared with analysis of covariance. 
Comparison of several groups of data was done with analysis of variance. A Ρ value 
of less than 0.05 was considered significant. Unless otherwise stated all values are 
expressed as means + standard deviation (SD). 
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Table 1. Effect of Recombinant Human Erythropoietin in Рте-Dialysis Patients 
(Correction Phase)* 
Haemoglobin Reticulocytes Thrombocytes 
mmol/L X 10l2/L x 109/L 
50 U/kg (я = 8) 
base-line 5.8 ± 0.4 
maximum 6.9 ± 0.8f 
100 U/kg (и = 8) 
base-line 4.9 ± 0.9 
maximum 7.3 ± 1.1 f 
150 U/kg (л = 8) 
base-line 5.2 ± 0.6 
maximum 7.5 ± 0.7f 
0.08 ± 0.04 
0.10 ± 0.04 
0.04 + 0.02 
0.11 ± 0.03t 
0.06 ± 0.06 
0.17 ± 0.08t 
243 ± 66 
260 ± 63 
250 + 57 
309 ± 95ф 
236 ± 58 
286 + 73f 
* Means ± SD are given. The maximum values for haemoglobin were recorded after eight weeks 
of r-HuEPO therapy. The maximum values for reticulocyte and thrombocyte counts were reached at 
week five and week four, respectively. 
t Ρ < 0.001, t Ρ < 0 01 for difference versus base-line. 
Results 
From the start of the maintenance phase one patient suffered from recurrent 
diverticulitis of the sigmoid colon. She developed bacterial peritonitis and 
intra-abdominal abscesses and subsequently died of sepsis. She was excluded from 
further evaluation. Two patients dropped out of the study at week 21 and week 28, 
respectively, because end-stage renal failure had developed and dialysis therapy was 
started. One patient received a kidney transplant from a living related donor at week 
30 of the study. 
A continuous increase in haemoglobin was noted within two weeks of starting 
r-HuEPO treatment. As shown in Table 1 the increase in haemoglobin after eight 
weeks was less in the 50 U/kg group than in both other dose groups (P < 0.05). The 
base-line haemoglobin in this group was greater than in the other dose groups, but this 
difference was not statistically significant. All patients, except one in the lowest 
dosage group, showed an increase in haemoglobin values. Figure 1 shows the course 
of the mean haemoglobin concentration and the mean dose of r-HuEPO per week for 
the whole study. From week 20 to 28 of the study a mean dose of 199 ± 139 U/kg 
of r-HuEPO maintained the haemoglobin at 7.4 ± 0.7 mmol/L. In the subgroup of 
patients who had pre-study haemoglobin > 5 mmol/L the dose of r-HuEPO 
administered ranged from 35 to 319 U/kg per week (mean 151 ± 103 U/kg, η = 17), 
whereas patients with pre-study haemoglobin < 5 mmol/L needed 213 to 600 U/kg 
(mean 335 ± 143 U/kg, η = 6). This difference was significant (P < 0.05). 
In the two highest dose groups an increase in reticulocyte counts was seen within one 
week of the start of r-HuEPO treatment. Reticulocyte counts reached a maximum at 
week five and remained constant thereafter during the correction phase (see Table 1). 
15 
haemoglobin 
(mmol/L) 
mean dose/week 
(U/kg BW) 
Figure 1. The effect of recombinant human erythropoietin on the mean ± SD 
haemoglobin values in pre-dialysis end-stage renal failure patients. R-HuEPO was given 
intravenously three times weekly in the first eight weeks and once weekly thereafter. 
In the maintenance phase reticulocyte counts decreased rapidly to base-line levels 
concurrent with reduction of the r-HuEPO dose. In the 50 U/kg group there was no 
change in thrombocyte counts, but the two other groups showed an increase with a 
peak at week four (see Table 1) and a decrease thereafter to a mean value that was not 
significantly different from controls. There was no change of total or differential 
leukocyte counts. All patients had normal or low serum ferritin concentrations. In spite 
of the oral iron supplementation there was a marked decrease of serum ferritin values 
of the same size in all groups (Figure 2). In the maintenance phase all ferritin 
concentrations returned to base-line values. Erythrocyte haemoglobin concentrations 
and mean cellular volumes were normal and remained so throughout the study. There 
were no changes in the routine clinical chemistry data. 
During the correction phase there were no significant changes in MAP in either of 
the three dose groups (see Table 2). Also, mean systolic and diastolic blood pressure 
and MAP did not change during the maintenance phase. The mean number of 
antihypertensive drugs prescribed increased from 1.5 + 1.1 before the start of 
r-HuEPO treatment to 2.0 ± 1.4 (P < 0.05) after 10 weeks of therapy but remained 
constant thereafter. In none of the five patients who were normotensive did 
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Figure 2. The effect of recombinant human erythropoietin therapy on the mean + SD 
serum ferritin values in pre-dialysis end-stage renal failure patients. All patients received 
oral iron supplementation throughout the study. Significant difference from baseline value 
is indicated by an asterisk. 
Table 2. Effect of Recombinant Human Erythropoietin on Mean Arterial Pressures 
(MAP) and Serum Creatinine Values (Correction Phase) 
r-HuEPO, υ/kg 
50 
(я = 8) 
99 ± 10 
98 ± 9 
723 ± 262 
780 ± 350 
100 
(л = 
105 
113 
8) 
+ и 
+ 9 
767 ± 257 
790 ± 244 
150 
in = 8) 
107 ± 23 
109 ± 24 
724 ± 248 
696 ± 187 
MAP, mm Hg 
before therapy 
after 8 weeks 
Serum creatinine, \imollL 
before therapy 
after therapy 
Values are means ± SD. 
hypertension develop, whereas in 9 of 18 patients on antihypertensive medication 
before the study, antihypertensive therapy had to be increased. However, in retrospect 
the mean blood pressure value measured at the time when the antihypertensive 
treatment was increased, was not significantly different from the mean pre-treatment 
blood pressure in this group of nine patients. 
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Figure 3. Average course of 1000/creatinine (ßmol/L) versus time in 14 patients, before 
and during r-HuEPO therapy. The broken lines represent the 95 % confidence limits on 
the predicted individual values for the fitted regression lines. 
Mean serum creatinine did not change during the correction phase (see Table 2). In 
14 patients enough data could be obtained to compare the time course of kidney 
function (1000/creatinine versus months) before and during r-HuEPO therapy. The 
reviewed periods were 20 months before therapy and seven months during therapy. 
We found no significant differences between the slopes before therapy 
(-0.036 + 0.002) and during therapy (-0.031 ± 0.004) (Figure 3). 
A flu-like syndrome, characterised by headache, malaise, and a feeling of cold or 
low-grade fever, was seen in two patients following the first injection of r-HuEPO. 
In one patient r-HuEPO therapy (100 U/kg thrice a week) was temporarily interrupted 
during the correction phase because of too rapid an increase of haemoglobin. One 
hypertensive patient, in whom hypertension had already been difficult to control, had 
a seizure after 20 weeks of treatment (haematocrit 0.41 L/L) when end-stage renal 
failure had evolved. R-HuEPO therapy was interrupted and continuous ambulatory 
peritoneal dialysis was started. In this study we observed no other major adverse 
reactions. In none of the patients antibodies against r-HuEPO developed. All patients 
reported an improved sense of well-being. 
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Discussion 
The results of this study show that r-HuEPO effectively increases the haemoglobin 
of pre-dialysis patients. In the correction phase we have observed consistent increases 
of haemoglobin in all dose groups. The difference in response between the groups 
which received 50 U/kg and those who received 100 or 150 U/kg three times a week 
is in agreement with the dose-dependency of the response found in haemodialysis 
patients (2). Since in seven out of eight patients an initial response was achieved by 
50 U/kg three times a week, this dose seems to be appropriate to start treatment, 
thereby avoiding too rapid an increase of haemoglobin. The optimal dosage scheme 
and way of administration during the maintenance phase has yet to be established. Our 
results show that an intravenous dose given only once a week gives a satisfactory 
result, but subcutaneous doses given three times weekly might be preferable not only 
because self-administration will then be possible, but also with regard to 
cost-effectiveness (5). 
In a study in haemodialysis patients that included several fixed dose levels of 
r-HuEPO during the initial treatment period no changes in thrombocyte counts were 
seen (2). In studies using an incremental dose regimen with low starting dose, some 
investigators observed a rise in thrombocyte counts (6, 7), whereas others found no 
change (1). Our data show a transient increase in thrombocyte counts at initial doses 
of 100 and 150 U/kg of r-HuEPO which was absent at the smallest dose. Whether an 
increase in thrombocyte counts, even if the values stay within the range of normal 
reference values, contributes, in concert with an increasing haematocrit and 
improvement of uraemic bleeding tendency, to the thrombotic episodes reported 
previously (1,2) requires further study. 
Our data on serum ferritin concentrations in the correction phase of the anaemia 
agree with the studies in haemodialysis patients (1, 2, 6, 7). Oral iron supplementation 
could not prevent a marked decrease in ferritin that was observed in all dose groups. 
However, the increase in haemoglobin occurred despite low ferritin values. We cannot 
exclude the possibility that the response to r-HuEPO has been limited by the 
apparently reduced availability of iron from the body iron stores. No parenteral iron 
was given additionally as all patients responded to r-HuEPO and the accelerated 
response that can occur after parenteral iron would have been undesirable. Moreover, 
in the maintenance phase all ferritin concentrations returned to base-line values, 
suggesting restoration of iron stores during protracted oral iron supplementation. 
In haemodialysis patients an increase in blood pressure was observed in both 
normotensive and hypertensive patients (2, 6, 8). Under the conditions of our study 
we were unable to demonstrate a direct relationship of r-HuEPO treatment to the 
occurrence of hypertensive episodes. Five normotensive patients remained 
normotensive. The number of antihypertensive drugs prescribed was increased in nine 
patients during the correction period, although their mean blood pressure at the time 
of medication change did not differ from base-line values. Our prescribing behaviour 
with regard to antihypertensive medication may have been influenced by the increased 
frequency of blood pressure measurements and the awareness of reported hypertensive 
episodes during r-HuEPO treatment in haemodialysis patients. 
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Time plots of the reciprocal of serum creatinine of patients with chronic renal failure 
often show a near-linear decline of kidney function (4). There is evidence that the 
progression of chronic renal failure might be a predictable consequence of the 
glomerular haemodynamic response to permanent widespread nephron injury (9). The 
assumed haemodynamic changes, ultimately leading to progression of renal disease, 
include increased glomerular pressure and flow. Increasing the haematocrit and 
thereby the blood viscosity could be detrimental for kidney function because it may 
increase vascular resistance and glomerular capillary pressure. In our study systemic 
hypertension was properly controlled. Although we did not check for dietary protein 
intake, it probably remained stable during the study since phosphate values did not 
change. Moreover, the target haematocrit did not exceed 0.40 L/L thereby avoiding 
extreme increases in blood viscosity. Under these conditions we found no change in 
the rate of progression of renal failure during seven months of r-HuEPO therapy 
compared to pre-treatment rates. Nor did we observe acute changes in kidney function 
during the correction phase of the anaemia. Obviously the group that we studied is too 
small and the observation time too short to permit definitive conclusions about a 
possible role of r-HuEPO treatment on renal function, but on the basis of our results 
it seems justified to conclude that such an effect will not be very large. However, it 
is clear that the role of the haematocrit in renal haemodynamics deserves further 
investigation. 
In conclusion, we have demonstrated that r-HuEPO therapy for the treatment of the 
anaemia of end-stage renal disease is also effective in pre-dialysis patients. Major 
adverse effects on blood pressure or on the rate of progression of chronic renal failure 
were not observed. An initial treatment dose of 50 U/kg, given intravenously three 
times a week, appears to be appropriate, thereby reducing the risks inherent in too 
rapid an increase of haemoglobin. Protracted oral iron supplementation in patients with 
normal or reduced iron stores is probably required to prevent long-term exhaustion of 
iron stores. 
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CHAPTER 2 
Evidence for Renal Vasodilation in Pre-Dialysis Patients 
during Correction of Anaemia by Erythropoietin 
L.A.M. Frenken, J.F.M. Wetzels, H.E. Sluiter, and R.A.P. Koene 
From the Department of Medicine, Division of Nephrology, University Hospital 
St. Radboud, Nijmegen, The Netherlands. 
Published in: Kidney International. 1992;41:384-387. 
Abstract 
• Background: Results from animal experiments have suggested that treatment 
with recombinant human erythropoietin (r-HuEPO) causes changes in renal 
haemodynamics which are detrimental to renal function. 
• Objective: To determine the effects of correction of the anaemia by r-HuEPO on 
glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). The effects 
of an oral dose of Captopril on GFR and ERPF, before and after correction of the 
anaemia, were also studied. 
• Design: Prospective analysis of an open investigation. 
• Setting: Outpatient clinic of an university hospital. 
• Patients: Eight pre-dialysis patients. 
• Intervention: Treatment with r-HuEPO to correct the anaemia of chronic renal 
failure. 
• Main outcome measures: Efficacy of the r-HuEPO treatment was assessed by 
measuring the increase in haematocrit. GFR (inulin clearance) and ERPF (PAH 
clearance) were measured before and at 89 ± 19 days after the start of r-HuEPO 
therapy. In each study 25 mg of Captopril was given orally after base-line values 
of GFR and ERPF had been obtained, and measurements were continued. 
• Results: Haematocrit increased from 0.24 ± 0.05 L/L to 0.39 ± 0.03 L/L. 
Base-line GFR, renal blood flow (RBF) and filtration fraction (FF) did not change 
during r-HuEPO therapy. At low haematocrit Captopril induced a significant increase 
in ERPF and RBF, and a decrease in MAP. After correction of the haematocrit the 
blood pressure lowering effect of Captopril remained unchanged. However, 
Captopril no longer induced changes in ERPF and RBF. 
• Conclusions: The increase in haematocrit had no adverse effects on GFR. The 
results suggest that changes in haematocrit may influence the effects of ACE 
inhibition on efferent vascular resistance. Therefore, the haematocrit should be 
taken into account when evaluating studies on the effects of ACE inhibition in the 
progression of chronic renal failure. 
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The introduction of recombinant human erythropoietin (r-HuEPO) for the treatment 
of the anaemia of chronic renal failure has renewed the interest in the effects of 
changes in haematocrit on haemodynamics and renal function (1-5). A major adverse 
event associated with r-HuEPO therapy is the increase in blood pressure. The 
haematocrit is the major determinant of blood viscosity at high and low rates of shear 
(6). The increase in whole blood viscosity and the loss of hypoxic vasodilation, 
resulting in an inappropriate increase in systemic vascular resistance, are suggested as 
potential causes of the increased blood pressure (7). 
Besides the adverse effects of systemic hypertension with regard to renal function, 
the increased haematocrit by itself also might affect the rate of progression of renal 
failure. Efferent arterioles are smaller in calibre and longer than afferent arterioles. 
According to Poiseuille's law, the increase in viscosity will cause a larger rise in 
efferent than in afferent vascular resistance. Also, due to ultrafiltration of plasma 
water in the glomerulus, haematocrit in the efferent arteriole always exceeds 
haematocrit in the afferent arteriole (8). This results in a disproportionate, passive 
increase in efferent vascular resistance. Changes in activity of the renin-angiotensin 
system also may play an active role, since plasma renin levels in dogs increase when 
haematocrit rises (9). 
In agreement with these theoretical considerations, important effects of haematocrit 
on renal haemodynamics were observed in patients with congenital cyanotic heart 
disease and cor pulmonale (10, 11). In these patients renal blood flow (RBF), and 
effective renal plasma flow (ERPF) were considerably reduced. Since glomerular 
filtration rate (GFR) decreased to a smaller extent, this resulted in an increased 
filtration fraction (FF). After acute reduction of the haematocrit in these patients, RBF 
and ERPF increased, FF fell, and proteinuria decreased. Also in experimental animals, 
FF varies directly with systemic haematocrit, with proportionally greater changes in 
ERPF than in GFR (12). More direct evidence for the influence of haematocrit on 
changes in renal haemodynamics stems from micropuncture studies in rats. An acute 
increase in haematocrit, induced by isovolaemic exchange transfusions, led to an 
increase in efferent arteriolar resistance, an increase in glomerular transcapillary 
hydraulic pressure gradient and an increase in FF (13). These studies showed that 
changes in renal arteriolar vascular resistance cause the changes in ERPF and FF in 
response to variations in systemic haematocrit. The presence of continuous glomerular 
hypertension in the rat may cause the development of focal segmental glomerular 
sclerosis and renal failure even after limited renal ablation (14). Increased glomerular 
capillary pressure also may contribute to the progression of renal failure in patients 
with renal disease (15). 
Recently, results of two studies in five-sixth nephrectomized rats treated with 
r-HuEPO suggested that r-HuEPO therapy may accelerate chronic renal failure, and 
worsen systemic hypertension and glomerular hypertension because of increased 
efferent arteriolar resistance (16, 17). Up to now, clinical studies in patients with renal 
disease, although not specifically designed to evaluate renal function, did not report 
acceleration of the rate of progression of renal failure measured as the slope of inverse 
plasma creatinine concentration (l/PCr) versus time (2-5). Yet, the rate of decline in 
l/PCr may not accurately reflect the decline in GFR. 
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In the present study, we have investigated the effects of r-HuEPO induced changes 
in haematocrit on renal function in pre-dialysis patients. 
Patients and Methods 
Patients 
Eight patients (four females, four males) with a history of progressive chronic renal 
failure participated in the study. The underlying renal diseases were: chronic 
glomerulonephritis in three, congenital hypoplastic kidneys in one, chronic 
pyelonephritis in one, reflux nephropathy with uninephrectomy in one, and unknown 
renal disease in two patients. The mean (± SD) creatinine clearance was 13 ± 5 
mL/min/1.73 m2. All patients were anaemic with haematocrits ranging between 0.16 
and 0.30 L/L. The median age was 33 years (range from 25 to 66 years). 
Hypertension was either absent (л = 4) or medically controlled (n = 4). 
Antihypertensive treatment consisted of metoprolol 200 mg daily (patient A), 
propanolol 3 dd 20 mg (patient C), atenolol 25 mg daily (patient F), or atenolol 25 mg 
and nifedipine 2 dd 20 mg (patient G). No angiotensin-converting-enzyme (ACE) 
inhibitors were prescribed before or during the study. None of the patients had 
received blood transfusions within three months of the start of the study. Dietary and 
medication regimens were stable for at least one month before study entry and 
attempts were made to keep them constant. The 24 hour excretion of sodium and urea 
did not change during the study period. 
Methods 
All patients gave written informed consent. The patients were given intravenous 
injections of r-HuEPO three times a week for eight weeks. The patients were 
randomly assigned to receive either 50 (n = 2), 100 (n = 3), or 150 (л = 3) units 
of r-HuEPO per kilogram of body weight. After the completion of this eight-week 
period r-HuEPO was injected intravenously once a week. The dose was three times 
the dose given in the former period, adjusted for response. Renal function 
measurements were done before r-HuEPO therapy and at 89 ± 19 days after the start 
of r-HuEPO therapy when the increased haematocrit was stable within the target range 
of 0.35 to 0.45 L/L for at least three weeks. 
The patients did not take food or drugs from 12 hours before the start of the renal 
function measurements until the end of the study. Smoking was not allowed in the 
same period. The patients were in a half-sitting position during the whole study, 
except for micturition. GFR (inulin clearance) and ERPF (PAH clearance) were 
measured using a continuous infusion technique. An isotonic solution of inulin 
(Inutest®, Laevosan, Linz, Austria) and para-aminohippuric acid (PAH, Merck Sharp 
& Dohme, West Point, Pennsylvania, USA) in distilled water was used as described 
elsewhere (18). Blood and urine samples were simultaneously collected at 45 minute 
intervals. Prior to the infusion the patients were given an oral water load of 15 mL/kg. 
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Table 1. Individual Data (Patients A-Η) on Renal Function and Effects of Captopril 
before and after 89 ± 19 Days of r-HuEPO Treatment* 
Study 
GFR 1 
GFR2 
ERPF 1 
ERPF2 
Period 
Base-line 
After Captopril 
Base-line 
After Captopril 
Base-line 
After Captopril 
Base-line 
A 
11 6 
12 6 
8 6 
10 2 
82 5 
95 7 
62 8 
В 
7 8 
6 6 
6 9 
6 4 
20 4 
19 9 
21 2 
С 
7 2 
9 2 
5 3 
6 3 
449 
61 1 
27 5 
D 
12 0 
14 8 
14 6 
13 2 
51 3 
61 7 
56 3 
E 
8 9 
9 1 
9 3 
8 6 
38 4 
442 
40 4 
F 
3 6 
7 1 
4 1 
4 2 
22 1 
44 6 
25 1 
G 
8 5 
8 9 
6 9 
7 1 
39 5 
48 4 
34 2 
H 
9 3 
8 2 
7 4 
4 1 
54 5 
52 0 
29 8 
After Captopril 62 5 21 9 36 8 58 5 40 4 24 3 37 9 15 9 
RBF 1 Base-Ime 107 1 25 2 66 3 711 48 1 30 9 47 3 77 6 
After Captopril 123 8 24 4 87 2 84 2 55 6 61 7 59 0 73 3 
RBF 2 Base-Ime 99 5 34 4 48 5 90 7 62 9 41 0 54 3 54 5 
After Captopril 98 2 34 7 65 7 96 7 65 7 39 5 60 1 29 7 
FF 1 Base-Ime 14 1 38 0 15 9 23 4 23 2 16 6 
After Captopril 13 2 33 3 15 1 23 9 20 7 15 8 
FF 2 Base-line 13 8 32 7 19 3 25 9 23 1 16 6 
After Captopril 16 4 29 1 17 2 22 6 212 17 0 
* GFR, ERPF, and RBF are expressed in mL/rmn/1 73 nf. RBF = ERPF/(1 - haematocnt), 
FF = 100 x GFR/ERPF The first studies were done before r-HuEPO therapy The second studies 
were done after the haematocnt had reached the target range, and was stable for at least three weeks 
Every next 45 minutes the urinary losses were replaced by an equivalent oral water 
load If urine flow was less than 100 mL/45 minutes an extra oral water load of 100 
mL was given Urine was collected by spontaneous micturition Mean arterial pressure 
(MAP, mm Hg) was measured every 15 minutes using a calibrated automatic recorder 
(Dynamap™) The mean MAP of every 45-minute interval was calculated as the mean 
of the three recordings during that interval Body weight was measured before and 
after the study After having obtained base-line values, 25 mg of Captopril was given 
orally at 210 minutes after the start of the infusion, and measurements were continued 
for another three hours The mean value of the two 45-minute GFR and ERPF 
21 6 
18 4 
20 1 
18 8 
17 1 
15 7 
24 8 
26 0 
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measurements obtained immediately before Captopril was compared with the mean 
value of two 45-minute intervals starting 45 minutes after Captopril. Clearances were 
calculated according to standard clearance formulas С = UV/P and expressed as mL 
per minute per 1.73 nr body surface. The FF was calculated as 100 x GFR/ERPF, 
and RBF was estimated using the formula: RBF = ERPF/(1 - haematocrit). During 
steady state the intra-individual coefficients of variation of the inulin and PAH 
clearances were 6.5 %, and 6.9 %, respectively. The intra-individual coefficients of 
variation between two separate measurements were 9.6 %, and 11.2 %, respectively. 
All results are expressed as means with standard deviations. Г-test procedures for 
paired samples and for independent samples were used for statistical analysis. 
Differences were considered significant at the 0.05 level. 
Results 
R-HuEPO therapy increased the mean haematocrit value from 0.24 ± 0.05 L/L to 
0.39 ± 0.03 L/L. In patient C, who had hypertension before r-HuEPO therapy, the 
dose of propanolol was increased to 3 dd 40 mg after seven weeks of therapy because 
of increasing blood pressure. In another hypertensive patient (patient G) nifedipine was 
replaced by minoxidil (2 dd 5 mg) after six weeks of r-HuEPO due to side effects. All 
four patients without antihypertensive medication prior to r-HuEPO therapy remained 
normotensive. Under these conditions there were no significant changes of systolic, 
diastolic, or mean arterial blood pressure throughout the study period. 
The individual data on renal function are given in Table 1. Base-line GFR and FF 
were comparable before and during r-HuEPO treatment (see Table 2). The RBF also 
remained unchanged, and the values of ERPF tended to decrease. These small changes 
in ERPF correlated well with the changes predicted from initial RBF and the change 
in haematocrit (r = 0.83, Ρ < 0.01). Moreover, in two patients in whom haematocrit 
values had returned to their initial values after eight months, the decreased value of 
ERPF at high haematocrit had also returned to the initial value, while RBF was 
unchanged (data not shown). During r-HuEPO therapy there was no significant change 
in 24 hour proteinuria when compared to pre-treatment values. 
Prior to r-HuEPO therapy a single 25-mg dose of Captopril resulted in a significant 
increase in RBF, when compared to base-line values (see Table 2). Despite a small, 
but nonsignificant increase in GFR, FF decreased significantly. After correction of the 
haematocrit by r-HuEPO therapy the blood pressure lowering effect of Captopril was 
identical to that in the first study. However, the captopril-induced rise in RBF and 
ERPF had disappeared completely. Since GFR remained stable, a change in FF was 
also absent. In four patients who were not yet on dialysis after 35 ± 1 weeks of 
r-HuEPO treatment, the measurements were repeated. In these patients we observed 
that a reaction to Captopril was still absent (data not shown). By contrast, in another 
patient, in whom haematocrit after eight months had returned to the initial value, the 
response to Captopril which was absent during high haematocrit was present again. 
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Table 2. Mean Values of Renal Function and Effects of Captopril before and after 
89 ± 19 Days of r-HuEPO Treatment* 
ERPF 
GFR 
FF 
RBF 
MAP 
u v A l b 
Before Γ-
Base-line 
44.2 ± 19.8 
8.6 ± 2.6 
21.2 ± 7.7 
59.2 ± 26.9 
111.5 ± 23.3 
1.4 ± 1.1 
HuEPO therapy 
After Captopril 
53.5 ± 21.5t,t 
9.6 ± 2.8 
19.5 + 6.5f 
71.2 + 29.0t,§ 
103.3 ± 21.9t 
1.4 ± 1.1 
During r-HuEPO therapy 
Base-line 
37.2 ± 15.1 
7.9 ± 3.2 
22.0 ± 6.0 
60.7 ± 23.0 
110.3 ± 15.8 
1.7 ± 1.3 
After Captopril 
37.3 ± 16.7 
7.5 ± 3.1 
21.1 ± 4.7 
61.3 ± 26.3 
103.7 ± 16.6t 
1.5 + 1.3 
* GFR, ERPF, and RBF are expressed in mL/min/1.73 rrf\ RBF = ERPF/(1 - haematocrit); 
FF = 100 x GFR/ERPF. MAP is expressed in mm Hg. Albumin excretion (UVAlb) is expressed in 
mg/minute. The values are expressed as means ± SD. 
t Ρ < 0.05 for difference between parameter before and after Captopril. 
+ Ρ < 0.05 for difference between changes after Captopril before and after r-HuEPO therapy. 
§ Ρ = 0.07 for difference between changes after Captopril before and after r-HuEPO therapy. 
Discussion 
Studies in five-sixth nephrectomized rats showed that anaemia retards the 
development of proteinuria and glomerular injury and reduces systemic hypertension, 
whereas treatment with r-HuEPO causes an acceleration of glomerular injury (17). 
These findings suggested that full correction of anaemia in pre-dialysis patients may 
prove harmful to residual renal function. However, in rats there was also a 
considerable rise in systemic blood pressure during r-HuEPO therapy. The remnant 
kidney model is a hypertensive model, in which systemic hypertension induces 
glomerular capillary hypertension, which is the major factor contributing to glomerular 
injury, hyperfiltration being much less important (14). In agreement with these 
findings it was recently shown that glomerular hyperfiltration was not accompanied 
by glomerular injury in a normotensive rat remnant kidney model (19). Whether 
r-HuEPO therapy without concomitant hypertension will cause identical injury in 
experimental animals has not been studied. Moreover, in the anaemia-protection model 
the accompanying iron depletion may have protected against additional tubulo-
interstitial injury and renal function deterioration (20). 
Recently, a clinical study of r-HuEPO therapy in pre-dialysis patients showed a 
significant increase in FF (0.27 ± 0.17 to 0.33 + 0.22) in four weeks (21). In these 
patients the mean haematocrit was only moderately increased from 0.21 ± 0.025 to 
0.27 + 0.024 L/L. More importantly, the mean MAP increased significantly from 
119.3 ± 18.3 to 134.1 ± 15.2 mm Hg. Yet, this increase in blood pressure was 
probably also related to the fact that these patients received no antihypertensive 
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treatment. In the present study the increase in haematocrit was larger, from 
0.24 ± 0.05 to 0.39 ± 0.03 L/L in 15.4 + 3.7 weeks. In our patients mean blood 
pressure was lower, and was kept constant throughout the study. Despite the 
considerable change in haematocrit, no significant alterations of GFR, RBF, or FF 
were observed. Although a change in the rate of decline in renal function cannot be 
excluded, the results of this and another study (5) do not suggest that a considerable 
increase in haematocrit has a major influence on kidney function. 
To investigate further the haemodynamic characteristics during treatment with 
r-HuEPO, we studied the effects of a single 25-mg dose of Captopril on renal function. 
We were interested to see if the expected blocking effect of Captopril on angiotensin 
II-mediated efferent vasoconstriction would be influenced by a change in haematocrit. 
Before r-HuEPO treatment there was a significant increase in RBF after Captopril, 
with a concomitant decrease in FF. Surprisingly, after correction of the haematocrit, 
Captopril no longer induced changes in RBF and FF, although the blood pressure 
lowering effect of Captopril was identical to that in the first study. In our study base-
line RBF remained unchanged, indicating that total renal vascular resistance did not 
change. This can be explained by either no change in renal vascular resistances, or by 
an increased passive vascular resistance combined with a decreased vascular tone. The 
observation that the rise in RBF after Captopril during anaemia, was absent when 
haematocrit had increased, favours the explanation that, with increasing haematocrit, 
RBF is maintained by the development of an efferent vasodilation, that cannot be 
increased further by Captopril. An additional effect of increasing haematocrit on 
afferent vascular resistance cannot be excluded. A captopril-induced efferent 
vasodilation with high haematocrit could have been masked by the concomitant 
decrease in blood pressure. However, since base-line blood pressure and the decrease 
in blood pressure after Captopril were similar before and after increasing the 
haematocrit, the observations still indicate different states. In one patient, in whom 
haematocrit after eight months had returned to the initial value, the previously 
disappeared response to Captopril during high haematocrit was present again. Since 
blood pressure, body weight and antihypertensive drugs had not changed, this suggests 
that the changes observed are indeed mediated by the change in haematocrit. 
One could argue that the PAH clearance does not adequately reflect renal plasma 
flow in patients with decreased renal function due to an incomplete extraction rate. 
Yet, even when PAH clearance would not estimate low renal plasma flow adequately 
when compared to situations with normal renal plasma flow, it is likely that changes 
in renal plasma flow would still be reflected in changes in PAH clearance. 
Results of several animal smdies suggest that ACE inhibitors are beneficial in 
reducing the rate of decline of GFR, by their specific effect on efferent vascular 
resistance, irrespective of their blood pressure lowering effect (22, 23). Prospective, 
randomised trials using ACE inhibition in patients with renal disease are currently 
under way. With regard to these studies, our data suggest that changes in haematocrit 
may influence the effects of ACE inhibition on efferent vascular resistance. Therefore, 
the haematocrit should be taken into account when evaluating studies on the effects of 
ACE inhibition in the progression of chronic renal failure. Also, treatment with ACE 
inhibitors for hypertension developing during r-HuEPO therapy would appear to offer 
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no specific advantages above other antihypertensive drugs The final answer to the 
question whether r-HuEPO changes the natural course of progression of renal failure 
in patients with renal disease, can only be given by large prospective trials, including 
precise renal function measurements and appropriate dietary and blood pressure 
control 
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In patients with progressive chronic renal failure anaemia generally becomes apparent 
when the creatinine clearance decreases below 25 mL/minute. Beneath this value a 
significant correlation of haemoglobin level with creatinine clearance exists, but large 
interindividual differences are observed. Some patients may retain normal haemoglobin 
levels even at very low creatinine clearances, e.g. in polycystic kidney disease, but 
most have decreased values. Uncomplicated anaemia in non-renal patients shows an 
inverse relationship between haemoglobin and plasma erythropoietin (EPO) levels. 
This relationship also exists in patients with haemolytic anaemia or anaemia of chronic 
inflammatory processes. In contrast, plasma EPO levels in patients with anaemia 
secondary to chronic renal diseases are inappropriately low for the degree of anaemia 
when compared to normal reference values. The lowest levels are found in anephric 
patients. This abnormal relationship between haemoglobin and EPO titres becomes 
normal after successful renal transplantation. The signs and symptoms of anaemia in 
patients with chronic renal failure do not differ from those seen in other patients with 
chronic anaemia. 
The high efficacy and the benefit of recombinant human erythropoietin (r-HuEPO) 
in the treatment of anaemia was first demonstrated in patients with end-stage renal 
failure undergoing haemodialysis. In spite of its high costs, r-HuEPO has become 
widely accepted for the treatment of anaemia in patients with end-stage renal failure 
who are treated by haemodialysis or peritoneal dialysis. In anaemic pre-dialysis 
patients the experience is more limited, but it has already become clear that, also in 
this group, treatment with r-HuEPO leads to an adequate haematological response. The 
overall reported experience now comprises long-term observations of more than 200 
patients. In all studies dose-related increases of haematocrit were observed during the 
correction phase and stable values could be maintained by individual dosing. Although 
a systematic comparison of dose requirements between dialysis and pre-dialysis 
patients has not been made, the available reports suggest that differences are not large, 
with possibly slightly smaller dose requirements in the pre-dialysis patients. 
In the first studies r-HuEPO was administered intravenously, but obviously this is 
not the most convenient way to treat outpatients. Subcutaneous self-administration 
offers an excellent alternative, thereby allowing for the use of lower dosages, as 
suggested from studies in dialysis patients (1). 
Similar to the observations in dialysis patients, pre-dialysis patients treated with 
r-HuEPO experience an improved sense of well-being and most often also an increase 
in appetite and physical activity. In a recent study, self-assessed scores of energy level 
and work capacity increased significantly in 65 patients as compared to 30 
placebo-treated patients (2). A significantly increased maximal work rate during 
exercise testing has also been reported in patients after correction of the anaemia (3). 
On the basis of these data, a strong case can be made for the institution of treatment 
with r-HuEPO for anaemia of chronic renal failure, before end-stage renal failure has 
developed. However, based on theoretical considerations and results from animal 
studies, objections have been raised against the use of r-HuEPO in pre-dialysis 
patients. The rise in haematocrit might adversely affect renal function and thus 
accelerate the rate of progression of renal failure via two mechanisms. First, 
correction of the anaemia with r-HuEPO is often accompanied by an increase in blood 
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pressure. The detrimental effects of systemic hypertension on renal function are 
well-established. Second, the rise in haematocrit has special sequelae for the renal 
vasculature, and this might cause renal damage independently of the effects of 
systemic hypertension. 
Influence of Increased Haematocrit on Blood Pressure 
Increased blood pressure, necessitating institution or increase of antihypertensive 
therapy, is the most important side effect associated with r-HuEPO treatment. It 
occurred in one third of the patients. It is not certain whether in all patients the rise 
in blood pressure was due to the increase in haematocrit. In the reported trials, control 
of blood pressure was probably more rigid during the treatment period than before. 
In one study it was found that the mean blood pressure at the time of increase in 
antihypertensive medication did not significantly differ from base-line values (4). 
Elevated blood pressure is not related to the dose of r-HuEPO, nor are the final 
haematocrit achieved or the rate of increase in haematocrit clearly involved. Increases 
in blood pressure occur particularly during the first four months of therapy, and blood 
pressure usually stabilizes thereafter. Acute increase in blood pressure during 
r-HuEPO therapy occasionally results in hypertensive encephalopathy and seizures. 
This complication is unrelated to the extent or rate of increase in haematocrit, and may 
occur also in previously normotensive patients. In 117 pre-dialysis patients randomly 
assigned to receive r-HuEPO (50, 100, or 150 U/kg) or placebo intravenously, three 
times a week, no important change in mean systolic or diastolic pressure was found 
in any treatment group. Also, changes in antihypertensive medications were not 
significantly different between r-HuEPO- and placebo-treated groups. Hypertension 
was reported in 26 of 86 (30 %) r-HuEPO-treated patients and in 6 of 29 (21 %) 
placebo-treated patients. This difference was also not significant, although a trend 
towards an increased number of hypertensive events was noted in the 150 U/kg 
treatment group, which also showed the fastest rate of increase in haematocrit (2). In 
a similar study in haemodialysis patients, clinically important increases in blood 
pressure were more frequent with r-HuEPO than with placebo (58 versus 37%; 
Ρ = 0.005) (5). 
R-HuEPO does not affect blood pressure in patients with normal renal function. The 
mechanisms of increased blood pressure related to r-HuEPO in chronic renal failure 
remain uncertain. An increase in systemic vascular resistance occurs in all these 
patients, whether or not blood pressure increases. The increase in haematocrit by 
treatment with r-HuEPO leads to an increase in whole blood viscosity and, 
consequently, in peripheral vascular resistance. Furthermore, correction of anaemia 
causes a reversal of anaemia-induced hypoxic peripheral vasodilation that is normally 
present in uraemic patients with anaemia (6). The potent natural vasodilator nitric 
oxide (endothelial-derived relaxing factor, ERDF) may be involved in this process. 
Nitric oxide can bind to haemoglobin, and it has been proposed that the increased 
haemoglobin may trap more of the nitric oxide produced by vascular endothelial cells 
and thus decrease vasodilation (7). The resulting increase in peripheral vascular 
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resistance then leads to systemic hypertension. Indeed, it has been shown that in 
patients with end-stage renal failure, a gradual increase in haematocrit by serial 
transfusions produced a rise in diastolic blood pressure and a fall in cardiac output (8). 
Patients in whom blood pressure increases during r-HuEPO therapy are characterised 
by an absence of adequate adaptive decrease in cardiac output. This may be due to 
abnormal cardiovascular autoregulation in these patients (9). Animal studies and 
clinical observations suggest that the rise in blood pressure at increasing haematocrit 
occurs in particular when there is a pre-existing vasoconstricted state or hypertension 
(6,9). Most studies on the changes in cardiovascular haemodynamics during r-HuEPO 
treatment have been done in haemodialysis patients and are generally in line with the 
results of the transfusion studies, demonstrating an increase in peripheral vascular 
resistance and systemic blood pressure and a decrease of cardiac output (10, 11). A 
preliminary report of a similar study in pre-dialysis patients suggests that the 
cardiovascular responses in these patients are comparable to those in haemodialysis 
patients (12). The information on the adrenergic regulation of vascular tone in renal 
failure with respect to haematocrit is limited. Beta2-adrenergic receptors mediate 
peripheral vasodilation, but this receptor system does not seem to be involved in 
haemodynamic changes in end-stage renal failure and r-HuEPO treatment (13). 
Postsynaptic alpha2-adrenergic receptors mediate vasoconstriction. There is evidence 
for an anaemia-mediated disturbance of alpha2-adrenergic receptor function in end-
stage renal failure, which leads to diminished vascular responsiveness to sympathetic 
stimuli. With correction of renal anaemia, receptor function seems to be restored with 
a resultant increased vascular reactivity, which may contribute to the increase in blood 
pressure during r-HuEPO therapy (13). No data exist about the role of the renin-
angiotensin system and of catecholamines in pre-dialysis patients. 
The overall conclusion can be that blood pressure tends to rise during treatment with 
r-HuEPO. This may occur especially during the correction phase of the anaemia, and 
it can be controlled rather easily by careful adjustment of the antihypertensive 
treatment. Serious problems with blood pressure can be prevented largely by a 
relatively slow correction of the anaemia and by aiming at target levels at or below 
the lower limit of normal (haematocrit of 0.30 to 0.35 L/L). Given the substantial 
benefit of r-HuEPO treatment there is no doubt that this limited trade-off with regard 
to antihypertensive medication will be acceptable in almost every pre-dialysis patient 
who has complaints of anaemia. 
Influence of Increased Haematocrit on Renal Haemodynamics 
An increase in blood viscosity causes a disproportionate, passive increase in renal 
vascular resistance in the efferent arterioles of the glomerulus relative to the afferent 
arterioles. This is explained by the presence of glomerular filtration on one hand, and 
the specific anatomical structure of the glomerular arterioles on the other. As a 
consequence of fluid removal by glomerular filtration there will be an increased 
haematocrit and thus an increased blood viscosity in the efferent arterioles. It is 
important to realize that whole blood viscosity is exponentially related to the 
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haematocrit. An increase in haematocrit from 0.20 to 0.25 L/L causes a much smaller 
increase in blood viscosity than an increase from 0.30 to 0.35 L/L. Thus, the effect 
of ultrafiltration on blood viscosity in the efferent glomerular arterioles will be larger 
after correction of the anaemia. In addition, the increase in viscosity will cause a 
larger increase of efferent than of afferent vascular resistance, because the efferent 
arterioles are smaller in calibre and are longer than the afferent arterioles. Other 
factors that might contribute to increased efferent vascular resistance are high values 
of plasma renin activity or of specific tissue renin activity with increasing haematocrit, 
leading to angiotensin-mediated vasoconstriction of the efferent arteriole (14, 15). 
When the anaemia is corrected, these changes might cause a rise in glomerular 
intracapillary pressure, independently of changes in systemic blood pressure. There 
is considerable evidence that a sustained increase in glomerular intracapillary pressure 
causes injury to renal structures resulting in focal glomerulosclerosis and progressive 
renal insufficiency (16). 
Results of Studies in Experimental Animals 
Micropuncture studies in rats, in which haematocrit was artificially raised, have 
confirmed the theoretical predictions discussed above. The rise in haematocrit led to 
a large rise in glomerular intracapillary pressure as a result of an increase in efferent 
arteriolar resistance (17). The detrimental effects of glomerular hypertension have 
been amply demonstrated in experiments in rats with partial renal ablation (16, 18). 
Gretz et al were the first to show that five-sixth nephrectomized rats treated with 
r-HuEPO had died from acute renal failure at a time when all control animals were 
still alive (19). Garcia et al (20) showed that the more rapid progression to renal 
failure in r-HuEPO-treated rats was accompanied by more extensive signs of 
glomerulosclerosis compared to control animals not receiving r-HuEPO. Using 
micropuncture techniques they demonstrated that the glomerular transcapillary 
hydraulic pressure gradient and efferent arteriolar resistance were highest in 
r-HuEPO-treated animals. By contrast, in animals made anaemic, glomerular 
intracapillary hypertension did not develop and a beneficial effect on the rate of 
progression of renal failure in these animals was observed. However, in these 
experiments a possible contribution of systemic hypertension to the increase in 
glomerular intracapillary pressure was not excluded. Systolic blood pressure was 
significantly higher in the r-HuEPO-treated animals compared to control and anaemic 
rats. Recently, preliminary results of comparable experiments have been reported, in 
which blood pressure was controlled with antihypertensive drugs (21). Treatment of 
r-HuEPO-induced hypertension with a combination of hydrochlorothiazide, reserpine, 
and hydralazine effectively prevented the rapid progression to renal failure that was 
seen in hypertensive, r-HuEPO-treated, control animals. This suggests that the rapid 
progression of renal failure in this model is mainly related to the systemic 
hypertension that occurs after correction of the anaemia. Since the combination of 
drugs used has no special effect on efferent arteriolar resistance, it is unlikely that 
glomerular hypertension, other than caused by systemic hypertension, played an 
important role in the increased rate of progression of renal failure induced by 
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r-HuEPO. Unfortunately, direct measurements of glomerular intracapillary pressure 
were not done in the latter study. Therefore, a definitive answer to the question of the 
role of glomerular hypertension in the rate of progression of renal failure in r-HuEPO-
treated rats with remnant kidneys awaits the results of micropuncture studies during 
antihypertensive treatment. 
Results of Clinical Studies 
The effects of haematocrit on renal haemodynamics have also been studied in 
humans. Obviously, direct measurements of glomerular intracapillary pressure cannot 
be obtained in the clinical situation. In the animal studies the increase of the 
glomerular transcapillary hydraulic pressure gradient is usually accompanied by an 
increase in filtration fraction (FF). Assuming that the filtration characteristics of the 
glomerular membrane (Kf) remain unaltered, changes in FF can be used in clinical 
studies as a parameter for changes in glomerular intracapillary pressure. Increased FF, 
as calculated from the ratio of glomerular filtration rate (GFR) and effective renal 
plasma flow (ERPF), was found in polycythaemic patients with congenital cyanotic 
heart disease and cor pulmonale (22, 23). Acute reduction of the haematocrit in these 
patients caused an increase in renal blood flow (RBF) and ERPF while FF decreased. 
A few groups have done renal haemodynamic studies in pre-dialysis patients before 
and at the end of the correction phase of the anaemia. The study that is most 
comparable to the experimental studies in the rat is that of Onoyama et al (24). They 
did these investigations in pre-dialysis patients, who apparently did not receive 
antihypertensive agents. Also, during the correction phase, the investigators made no 
attempt to correct hypertension when it occurred. In this way they studied seven 
patients before and after four weeks of treatment. At this time the mean haematocrit 
had increased from 0.21 to 0.27 L/L. They observed a non-significant decrease in 
ERPF accompanied by a small, non-significant increase in GFR. As a result there was 
a significant rise in FF. As in the rat experiments, this was accompanied by a 
significant rise in blood pressure from a mean pre-treatment value of 171/93 mm Hg 
to 190/105 mm Hg after four weeks. Another preliminary report also showed a 
significant rise in median FF after correction of the anaemia with r-HuEPO in 12 
pre-dialysis patients (25). However, this report gives no information on blood pressure 
changes or on antihypertensive treatment. In two other studies, in which renal 
haemodynamics were measured, blood pressure was carefully kept under control by 
antihypertensive drugs (26, 27). Together, these studies comprised observations in 16 
patients. Neither ERPF, nor GFR, nor FF had changed significantly at eight to 18 
weeks after initiation of r-HuEPO treatment, while haematocrits had risen to low or 
normal values. The clinical results are thus in line with the experimental studies. In 
the clinical situation possible detrimental changes in glomerular intracapillary pressure, 
as derived from increases in filtration fraction, seem to be prevented by effective 
antihypertensive treatment. 
In the study of renal haemodynamics in our own patient group we have tried to 
answer another question that we thought relevant to the way in which hypertension 
should be treated in these patients. We reasoned that, on the basis of theoretical and 
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experimental observations, angiotensin-converting-enzyme (ACE) inhibitors would be 
the best candidates for treatment of r-HuEPO-induced hypertension, since they also 
preferentially cause vasodilation of the efferent arterioles of the glomerulus and are 
thus best suited to prevent the presumed rise in glomerular intracapillary pressure. To 
test this hypothesis, we administered 25 mg of Captopril orally to eight pre-dialysis 
patients, who underwent measurements of ERPF (PAH clearance) and GFR (inulin 
clearance) before and after correction of their anaemia by r-HuEPO (27). Before 
correction of the anaemia, Captopril induced, as expected, a significant increase in 
ERPF, together with a decrease in mean arterial pressure and calculated renal vascular 
resistance (RVR). GFR remained unchanged and consequently FF also decreased. 
After correction of the haematocrit at eight weeks, base-line GFR, ERPF, RBF, and 
FF had not changed significantly. Also, the blood pressure lowering effects of 
Captopril remained unchanged. By contrast, and somewhat unexpectedly, 
administration of Captopril did not longer induce changes in ERPF or RVR. Since 
GFR also remained stable, FF did not change. 
The absence of an effect of Captopril on renal haemodynamics appeared to be 
sustained. Similar results were obtained when we repeated these renal function studies 
in four patients after a mean treatment period of 35 weeks. On the other hand, the 
renal response to Captopril reappeared in one patient whose haematocrit had fallen to 
the pre-treatment value. These results are highly suggestive for a mechanism of 
adaptive efferent renal vasodilation in pre-dialysis patients treated with r-HuEPO. 
Thus, changes in haematocrit may influence the effects of ACE inhibition on efferent 
vascular resistance. Therefore, treatment with Captopril for hypertension developing 
during r-HuEPO therapy does not seem to offer specific advantages over treatment 
with other antihypertensive drugs. The results of the above-mentioned rat studies, in 
which treatment with antihypertensive drugs without specific effects on efferent 
vascular resistance (hydrochlorothiazide, reserpine, hydralazine) completely prevented 
the r-HuEPO-induced acceleration of renal failure, are in keeping with these clinical 
findings. 
Estimation of Long-Term Effects of r-HuEPO on Renal Function in Humans 
The final answer to the question whether correction of uraemic anaemia with 
r-HuEPO changes the natural course of progression of renal failure, can only be given 
by long-term investigations in large groups of patients. Unfortunately, the limitations 
of these studies are many fold. The problems start already with the choice of the most 
suitable marker for GFR. Measurement of inulin clearance, the 'gold standard' for the 
estimation of GFR, is inconvenient in patients because of the associated 
time-consuming procedures. Moreover, the need for frequent serial determinations 
over prolonged periods of time renders this test impractical for use in prospective 
studies involving large numbers of patients. Radio-isotope-labelled compounds can 
serve as alternative filtration markers. However, although the procedures involved are 
generally less laborious than inulin studies, they remain relatively time-consuming for 
the patients. Also, it has not been firmly established that the calculated plasma or renal 
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clearances of these compounds correctly reflect the true GFR during all phases of 
renal functional deterioration. The repeated low radiation exposure is another 
drawback in large-scale studies. Finally, the variability among patients in the rate of 
decline in GFR, expressed as the coefficient of variation (CV), has been reported to 
be 100 % or greater. This implies that very large numbers of patients are required to 
assess statistical differences with sufficient power (28). Given these limitations, it is 
not surprising that results of large-scale and long-term studies estimating progression 
of renal failure in r-HuEPO-treated patients with clearance techniques have not been 
reported. A few years ago a study using iothalamate clearance as a marker was started 
in the United States (29), but till now the results of this study are not available. In 
view of the difficulties encountered in studying long-term effects on renal function 
with exact clearance techniques, the question arises whether it is possible to obtain 
equally useful information by simpler methods. 
Serum creatinine (SCr) is the most widely used marker of GFR in clinical practice. 
The level of SCr is determined by the rate of production of creatinine from creatine, 
its volume of distribution, and by creatinine clearance. However, several confounding 
factors influence SCr. These factors include the amount of creatinine derived from 
exogenous sources, functional and drug-induced changes in tubular secretion of 
creatinine, metabolism of creatinine, interference with the determination of creatinine, 
and changes in its endogenous production. Therefore, SCr does not provide an accurate 
estimate of GFR. However, when all these confounding factors would be constant, 
changes in SCr are supposed to reflect changes in renal function. In this situation only 
the influence of changing tubular secretion of creatinine associated with declining GFR 
will play a role. Recently, it was shown that after oral administration of Cimetidine, 
an H2-receptor antagonist that also inhibits tubular secretion of creatinine, the 
creatinine clearance (CCr) can be used as a reliable measure of GFR within a broad 
range of renal function (30). The reproducibility of this method is still under 
investigation. 
Several investigators have observed that the reciprocal of SCr decreases linearly with 
time, suggesting that the rate of decline is related to the rate of decline in CCr (31). 
Since in individual patients a high correlation coefficient of the slope can be observed, 
the individual progression of renal failure can often be predicted, provided that 95 % 
confidence intervals are taken into account. Serial measurements of SCr over a 
prolonged period of time in large numbers of patients are relatively reliable and cheap. 
However, even when designing a study based on SCr measurements, several additional 
problems are encountered. Uraemic anaemia seldom occurs until GFR decreases below 
30 mL per minute. In a prospective study, many of the patients with a rather rapid 
decline in renal function will require dialysis before sufficient follow-up data have 
been obtained. Consequently, the answer could only be given for patients with a less 
rapid progression of renal failure. During r-HuEPO therapy various effects might 
increase SCr, including increased dietary protein intake due to improved appetite, or 
increased muscle mass due to improved exercise capacity. In all these cases the slope 
of the reciprocal SCr versus time would become more negative. Factors that could 
improve the slope, by lowering SCr, include better dietary adherence and better blood 
pressure control. A simple 'study effect' by more frequent check-ups and better 
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general patient care might also improve clinical outcome. 
Slopes of the reciprocal SCr versus time are generated by linear regression analysis 
of SCr on time (Y on X regression). This procedure allows to predict individual 
(reciprocal) SCr values and 95 % confidence intervals (CI) for a given time. The CI 
broadens rapidly when the number of data points falls below 20 (as a consequence of 
the percentage points of the / distribution). A reasonable estimate can still be acquired 
in many cases with 10 data points. Also, the slope will be more reliable when data 
points are obtained over a sufficiently long interval. Clusters of data points, obtained 
within a short period of time, may strongly affect the slope. Therefore, data points 
preferably should be equally distributed over the observation period. If creatinine 
values are obtained each month, one would still need approximately one year before 
and one year after institution of therapy to construct a reliable slope. Adequate 
statistical techniques should be applied to compare two slopes within the same 
individual. Recently, the application of a statistical method to search for breakpoints 
in the regression lines of the patients has been advocated (32, 33). This method 
determines whether two lines fit the data from each patient better than a single line. 
However, inappropriate use of this method can give erroneous results, since multiple 
breakpoints are ignored and differences in the position of two parallel slopes are not 
correctly identified. A better approach is the use of analysis of variance, including 
analysis of covariance, on several combinations of two or more sequential slopes fitted 
to the data points. 
The number of patients needed to do a study of the rate of decline in GFR depends 
upon the variation of the slopes, that is the standard deviation (SD) of the mean slope, 
also expressed as coefficient of variation (CV = SD/mean x 100), and upon the 
hypothesized difference one wants to detect. Large numbers of patients are needed to 
detect small differences. For instance with a CV of 100 %, a sample size of 1250 
patients is required to detect a hypothesized difference of 10 % in mean slopes before 
and after therapy (one-sided testing; two-sided a error of 0.05 and one-sided power 
of 0.80). The answer to the question might be restricted to assessing whether 
institution of r-HuEPO therapy, while providing standard nephrological care, would 
necessitate institution of dialysis at an earlier time. From a practical point of view we 
are not interested when renal function improves or does not change, but only when it 
deteriorates. This would allow for one-sided statistical testing, thereby somewhat 
reducing the number of patients needed. This number can be reduced further when 
patients function as their own controls by comparing slopes before and during therapy. 
Also the CV of serial measurements in individual patients will be smaller than between 
measurements in different individuals. Inclusion of a control group not treated with 
r-HuEPO is not absolutely necessary. 
In several studies mean slopes have been compared before and after correction of the 
anaemia (3, 4, 26, 29, 34). These studies comprised altogether 132 patients. The mean 
follow-up in these studies ranged from seven to 12 months. In none of these studies 
significant changes in the mean slopes of the inverse SCr values versus time were 
detected after institution of r-HuEPO therapy, suggesting that there were no changes 
in the rate of progression of renal failure. The data, as they are presented in these 
studies, do not allow for a detailed meta-analysis or estimation of their statistical 
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power. 
We have collected data on 40 patients who were included in two multicentre studies 
to assess the efficacy and safety of r-HuEPO treatment in pre-dialysis patients. The 
studies were designed to collect at least 10 SCr values before study entry with at least 
monthly intervals. Follow-up time should at least comprise an equal period. Five 
patients had to be excluded because of insufficient follow-up data, three because of 
interventions in the pre-treatment phase that had significantly changed renal function 
shortly before the start of therapy, five because their creatinine clearances were below 
8 mL per minute before the start of therapy, and five because the slope was positive 
before therapy. It is important to note that in these five latter patients no significant 
change in slopes occurred. These data are given to illustrate that many patients have 
to be excluded if strict admission criteria are applied. The mean slope, calculated from 
the data of the remaining 22 patients, improved from -0.01917 before treatment to 
-0.01147 (1000/(Mmol/L)/day; Ρ < 0.003) after correction of haematocnt. 
On the basis of the current information it can be expected that the presumed 
detrimental effect of correction of the anaemia on renal function, if any, will not be 
very large. Although it might be of academical interest to exclude with certainty 
whether small changes in the rate of progression will occur during treatment with 
r-HuEPO, this does not seem to be very important from a clinical point of view. It is 
clear that the benefits of treatment with recombinant human erythropoietin outweigh 
such a, probably small, adverse effect on renal function. Therefore, it appears not 
very practical to put more effort in large-scale studies to trace such adverse effects. 
The general conclusion, therefore, can be that the criteria for treating pre-dialysis 
patients should be similar to those used in dialysis patients. It remains of fundamental 
importance that blood pressure is carefully monitored and controlled during this 
treatment. 
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Abstract 
• Objective: To determine the efficacy and safety of intraperitoneal administration 
of recombinant human erythropoietin (r-HuEPO) in CAPD patients, compared to 
subcutaneous r-HuEPO. 
• Design: Prospective analysis of an open, non-randomised investigation. 
• Setting: Outpatient CAPD clinics in two university hospitals. 
• Patients: Nine adult CAPD patients receiving r-HuEPO intraperitoneally, and eight 
patients receiving r-HuEPO subcutaneously. 
• Intervention: One hundred units of r-HuEPO per kilogram of body weight were 
administered three times a week for eight weeks or until the target haematocrit of 
0.35 L/L was reached. Thereafter, dosages of r-HuEPO were adjusted for response. 
Intraperitoneal r-HuEPO was administered in one litre of dialysis solution during the 
night. 
• Main outcome measures: Efficacy was assessed by measuring the increase in 
haemoglobin. Tolerance was assessed by monitoring side effects. 
• Results: In the first eight weeks of treatment haemoglobin concentrations 
increased from 4.0 ± 0.8 mmol/L to 6.1 ± 1.0 mmol/L (P < 0.0005) in the 
intraperitoneally treated group. In the subcutaneously treated group haemoglobin 
increased significantly faster {P < 0.05) from 4.5 ± 0.3 mmol/L to 7.4 ± 0.7 
mmol/L [P < 0.0005) in the same period of time. Antihypertensive medication had 
to be increased or instituted in most of the patients in both groups. The incidence 
of peritonitis in the intraperitoneally treated group was not increased when 
compared to the pre-treatment incidence. 
• Conclusions: The subcutaneous administration of r-HuEPO is superior to 
intraperitoneally administered r-HuEPO with regard to the required dosages. 
However, the results of this study show that intraperitoneal administration of 
r-HuEPO might be a convenient and safe alternative when subcutaneous 
administration is undesirable. 
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In end-stage renal failure most patients have a marked hypoproliferative anaemia, 
which is only slightly affected by dialysis treatment. In patients treated with 
continuous ambulatory peritoneal dialysis (CAPD) haemoglobin has been reported to 
be higher than in haemodialysis (HD) patients. The values increase particularly during 
the first months of CAPD (1-11). In addition to better control of overhydration and 
increased red cell survival time (12, 13), improved erythropoietin effectiveness may 
be responsible for the increase in red cell mass (5, 9, 12). These phenomena have 
been attributed to better removal of 'middle molecule' uraemic toxins that affect 
erythropoietin effectiveness and red cell survival time (3, 8, 14, 15). Increasing 
erythropoietin production (8, 16), and improved protein metabolism (17) might also 
be important. The relationship between the degree of anaemia and in vitro inhibition 
of erythropoiesis by sera of CAPD and HD patients is still controversial (14, 18, 19). 
Although CAPD patients seem to have higher erythropoietin values than patients on 
HD (10, 11), no consistent increase of erythropoietin values during therapy has been 
observed (4, 9, 18, 20). In addition, no strong correlation has been found between 
serum erythropoietin values and haematocrit in CAPD patients (3, 10, 11, 15). Since 
erythropoietin values relative to haematocrit are still inappropriately low, the primary 
cause of the anaemia is now considered to be a relative deficiency of erythropoietin 
production. 
Recombinant human erythropoietin (r-HuEPO) has been proven to be an effective 
treatment for the anaemia of chronic renal failure when given intravenously (IV) to 
haemodialysis patients (21, 22). However, IV administration of r-HuEPO, two or 
three times a week, would be inconvenient in CAPD outpatients. Subcutaneous (SC) 
administration has been shown to be the most convenient and cost-effective alternative. 
But subcutaneous administration in children, in particular, can cause considerable 
psychological distress. Therefore, we carried out a feasibility study to establish the 
efficacy and the clinical safety of multiple doses of r-HuEPO after intraperitoneal (IP) 
administration compared with subcutaneous administration, in patients with end-stage 
renal failure treated with CAPD. 
Patients and Methods 
Patients 
Twenty CAPD outpatients eligible for r-HuEPO therapy were included in the study 
after having given informed consent. Two patients were excluded from evaluation 
because they received a kidney transplant in the first week of the study. One patient 
in the intraperitoneal^ treated group was excluded because of recurrent severe 
menorrhagic bleeding from the start of the study. The remaining 17 patients received 
r-HuEPO either intraperitoneal ly (n = 9) or subcutaneously (n = 8). Their median 
age was 33 years (range 19 to 70), and the median duration on CAPD was 26 months 
(range 5 to 45). None of the patients had diabetes mellitus. Twelve patients were 
females. Between the two groups no significant differences were found for base-line 
haematological values, age, cause of renal failure, duration of CAPD, and sex distribution. 
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All patients had anaemia of chronic renal failure with haemoglobin ranging from 3.1 
to 5.2 mmol/L and haematocrit from 0.14 to 0.25 L/L. Three intraperitoneally treated 
patients received regular blood transfusions before r-HuEPO therapy. Three of the 
eight patients in the SC group and three of the nine patients in the IP group were 
treated for hypertension prior to r-HuEPO treatment. Oral iron supplementation was 
instituted when serum ferritin values were below 200 /ig/L. The study protocol was 
approved by the local Hospital Ethics Committees. 
Methods 
Prior to participation in the study the patients practised self-administration with a 
placebo. After a two-week period of base-line measurements all patients administered 
100 units of r-HuEPO (Boehringer Mannheim GmbH, Germany) per kilogram of body 
weight (U/kg) per injection, three times a week for eight weeks or until the 
haematocrit exceeded the target value of 0.35 L/L. After this period the dosages of 
r-HuEPO were adjusted for response, at least every four weeks. Dose adjustments 
were made in steps of 25 U/kg per injection. All dosages were rounded off towards 
the nearest 1000 U. When the haematocrit exceeded 0.40 L/L, r-HuEPO was withheld 
until the haematocrit had decreased to below the target value. When severe 
hypertension occurred, no r-HuEPO was given until blood pressure was under control. 
IP administration was replaced by SC r-HuEPO when peritonitis occurred. 
Before study entry all patients performed four 2 litre or 1.5-litre exchanges per 24 
hours. In the patients who administered r-HuEPO intraperitoneally, the volume of the 
nightbag was reduced to one litre (1.5 % or 1.36 % glucose) three times a week. 
Immediately before infusion r-HuEPO was dissolved into at least a 10 mL volume and 
injected slowly into the bag via the additional tube devised for sampling and injection. 
The patients used needles that were long enough to inject the solution directly into the 
bag, and ensured that no fluid remained in the tube. The dialysis fluid was not mixed 
before infusion to prevent adherence of r-HuEPO to the bag. SC injections of 
r-HuEPO were given in the thighs. 
The patients visited the outpatient clinic two times a week in the correction phase, 
and once a week thereafter. At these intervals haemoglobin, haematocrit, and blood 
cell counts were done, and blood pressure was measured. Serum chemistry was 
monitored every two weeks. 
To prove that r-HuEPO is stable in various dialysate glucose solutions, studies in the 
laboratories of Boehringer Mannheim GmbH (Mannheim, Germany) showed that there 
was no significant progressive loss of biological activity (mouse spleen assay) of 
r-HuEPO incubated at 37 °C in 1.5 %, 2.3 % and 4.25 % (commercially available) 
glucose solutions for periods up to 20 hours. In these solutions no aggregates of the 
hormone could be demonstrated using high performance liquid chromatography (data 
not shown). Due to technical problems concerning the radio-immuno-assay (RIA)-
based determination of r-HuEPO in peritoneal dialysis fluids, we were not able to 
calculate recovery rates of r-HuEPO from these fluids in patients. 
Differences from base-line values within the groups were evaluated using Student's 
/-test for paired data. Comparison of several groups of data was done with analysis of 
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Figure 1. Mean (SD) haemoglobin values during the correction phase in С APD patients 
treated with intraperitoneal erythropoietin (л = 9), or subcutaneous erythropoietin 
(« = 8)· 
variance. A Ρ value of less then 0.05 was considered significant. Unless otherwise 
stated all values are expressed as means + standard deviation (SD). 
Results 
In the subcutaneously treated group one patient left the study at week 18, because 
r-HuEPO had to be withheld due to severe hypertension. In two more patients 
r-HuEPO therapy was stopped for a prolonged period of time due to high haematocrits 
after week 18. Another patient discontinued r-HuEPO treatment at week 10, when his 
haemoglobin had reached 8.4 mmol/L. One patient received a kidney transplant at 
week six of the study. In one patient С APD was replaced by haemodialysis after 
abdominal surgery in week 18. The remaining two patients completed the 26 weeks' 
follow-up. In two patients IP administration of r-HuEPO was replaced by SC 
r-HuEPO in week 22 after peritonitis had occurred. 
A continuous rise in haemoglobin and haematocrit occurred within two weeks of 
beginning r-HuEPO (Figure 1). Mean haemoglobin in the IP group increased from 
4.0 ± 0.8 to 6.1 ± 1.0 mmol/L (P < 0.0005) after eight weeks of treatment. In the 
SC group haemoglobin increased from 4.5 ± 0.3 to 7.4 ± 0.7 mmol/L (P < 0.0005) 
in the same period. Haematocrit increased from 0.19 ± 0.04 to 0.29 ± 0.05 L/L 
(P < 0.0005) in the IP group, and from 0.22 ± 0.01 to 0.37 ± 0.04 L/L 
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Figure 2. Mean (SD) reticulocyte counts during the correction phase in CAPD patients 
treated with intraperitoneal erythropoietin (n = 9), or subcutaneous erythropoietin 
(n = 8). 
(P < 0.0005) with SC r-HuEPO. The rate of increase in haemoglobin and haematocrit 
in the subcutaneously treated group was twice the rate in the intraperitoneally treated 
group (P < 0.05). In the SC group a 50 % increase in haematocrit was reached after 
4.5 weeks, whereas an equal increase in the IP group occurred after nine weeks of 
treatment. In the maintenance phase the mean IP dose per injection was 85 ± 45 U/kg 
(range 40 to 130 U/kg, л = 9), three times a week. 
In the intraperitoneally treated group mean thrombocyte counts increased 
significantly, from 227 ± 50 to a maximum of 292 ± 55 x 109/L (P < 0.02) after 
seven weeks of treatment. No persistent change from base-line thrombocyte counts 
(225 ± 60 x 109/L) was observed in the SC group. An increase (P < 0.02) in mean 
reticulocyte counts was seen after two weeks of treatment in the IP group, and after 
one week in the SC group (Figure 2). During the first six weeks of treatment, mean 
reticulocyte counts were significantly higher in the SC group when compared to the 
IP treated group. There was no significant change of total leukocyte counts. Prior to 
r-HuEPO therapy median ferritin concentrations were significantly higher in the IP 
group. Serum ferritin values decreased significantly in six patients in each treatment 
group. 
During 210 treatment weeks in the IP treated group six episodes of peritonitis 
occurred in five patients. In the SC group two episodes of peritonitis occurred in one 
patient, whereas the follow-up in this group was 140 treatment weeks. In equally long 
periods before r-HuEPO treatment, five episodes of peritonitis occurred in three 
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patients in the IP group, and five episodes in two patients in the SC group. Median 
systolic and diastolic blood pressure did not change throughout the study. However, 
increased antihypertensive therapy was required in all three patients in the IP group 
and in two of the three patients in the SC group who where on antihypertensive 
medication prior to the study. In four intraperitoneally treated patients and two 
subcutaneously treated patients antihypertensive medication had to be instituted. 
Subcutaneous r-HuEPO was well tolerated and did not cause local pain or side 
effects. All patients mentioned an increase in well-being and in exercise tolerance. 
Blood transfusions were not longer required by the patients who needed regular blood 
transfusions prior to r-HuEPO therapy. In two female intraperitoneally treated patients 
menstrual bleedings that were irregular prior to r-HuEPO therapy became regular and 
more abundant during the treatment period. In one other patient who had secondary 
amenorrhoea, normal menstruations resumed within one month of beginning IP 
r-HuEPO therapy. No significant changes in clinical chemistry parameters were 
observed. 
Discussion 
It has been shown recently that the mean bioavailability of SC r-HuEPO, ranged 
from 18 % to 49 % of that after IV administration (23-25). These investigations also 
revealed that after IP administration the mean bioavailability was even lower, ranging 
from 3 % to 7 %. These studies suggested that SC and especially IP r-HuEPO would 
not be effective therapeutic approaches. However, clinical studies demonstrated that 
SC r-HuEPO allowed for using even lower dosages than IV r-HuEPO to obtain the 
same therapeutic effect (26). 
The efficacy of SC r-HuEPO in CAPD patients and in patients treated with 
continuous cyclic peritoneal dialysis has now become established (27-31). The results 
of the present study show that IP r-HuEPO is also effective. However, with SC 
r-HuEPO the rate of correction of the anaemia was twice that of IP r-HuEPO. Three 
female patients in the IP group suffered from an important increase in menstrual blood 
loss during the correction phase of the anaemia. Although serum ferritin values in the 
IP group were higher than in the subcutaneously treated group, it cannot be excluded 
that these blood losses influenced the rate of increase in haematocrit. Recently a study 
in children treated with CAPD showed similar results when IP r-HuEPO was 
administered three times a week in a 20 mL/kg overnight volume (32). 
The above-mentioned pharmacokinetic studies with IP r-HuEPO were done with an 
injection of r-HuEPO into two-litre dialysis bags, with dwell times ranging from 4 to 
12 hours. The results were in contrast with the 60 % absorption of 125I-erythropoietin 
from the peritoneal cavity in the uraemic rabbit after a six-hour dwell (33). Absorption 
from the dry peritoneal cavity after 24 hours even reached 97 %. It is not known by 
which mechanism r-HuEPO (molecular weight 34 000 dalton) is absorbed from the 
peritoneal cavity. However, it has been recently demonstrated that the disappearance 
of intraperitoneally administered macromolecular solutes takes place mainly by 
lymphatic absorption. In CAPD patients absorption rates of about 1.5 mL/minute are 
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found (34-37). Therefore, theoretically one would expect that the bioavailability of a 
fixed dose of IP r-HuEPO would increase with longer dwell times and with lower 
intraperitoneal dialysate volumes. In the ideal situation IP r-HuEPO should then be 
administered undiluted. Since in many outpatients changes in the day-time dwell 
schedule are inconvenient, we preferred to reduce the overnight volume to one litre 
three times a week in this study. This did not interfere significantly with solute 
clearances as judged from the unchanged clinical chemistry data. 
Several other reasons than return of unused r-HuEPO in dialysate effluent might 
explain the higher dosage requirements of IP r-HuEPO. IP degradation of r-HuEPO 
was excluded by in vitro studies as mentioned in the methods section. Adsorption of 
r-HuEPO onto the PVC of both fluid containers and connecting tubes also might 
reduce the amount of r-HuEPO available (38). However, when the r-HuEPO solution 
is slowly injected into the bag, ensuring that no fluid remains in the injection tube 
connected to the bag, mixing with the rather viscous CAPD dialysate will only occur 
to a small extent. Immediate infusion of the dialysate will minimize the adherence of 
r-HuEPO to the bag. Analysis by bioassay of a limited number of dialysate samples 
taken immediately after infusion of the dialysate showed no significant differences in 
r-HuEPO concentrations compared to the predicted values, when IP residual volumes 
were taken into account (data not shown). However, more precise measurements await 
the solution of technical problems associated with the RIA determination of r-HuEPO 
in dialysis fluids. 
In some studies with IV r-HuEPO, increases in thrombocyte counts were observed 
(39-41). This was not observed using lower dosages of SC r-HuEPO. We were 
surprised to see that in the IP group, in contrast to the SC group, mean thrombocyte 
counts increased significantly, despite a lower rate of increase in haematocrit and 
significantly lower reticulocyte counts. However, in none of the patients did the 
thrombocyte counts exceed the upper limit of normal. 
Increases in antihypertensive drugs prescribed or institution of antihypertensive 
therapy in previously normotensive patients occurred in both treatment groups, 
independent of the rate of increase in haematocrit. The overall incidence of peritonitis 
during the study did not differ from the pre-treatment period in the intraperitoneal^ 
treated group. Our experience suggests that with careful training the additional risk of 
peritonitis with IP administration of r-HuEPO is minimized, similar to the results with 
IP administration of insulin in diabetics (42). 
Although SC r-HuEPO is superior for the treatment of the anaemia associated with 
chronic renal failure, the results of this study show that IP r-HuEPO might be a 
convenient and safe alternative when SC administration is undesirable. Moreover, it 
can be concluded that standard descriptive pharmacokinetics alone are not appropriate 
to predict the biological response to r-HuEPO. Further improvement of the IP efficacy 
might be achieved by reducing the volume in which r-HuEPO is administered (33). 
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Abstract 
• Objective: To assess differences in pain experienced after subcutaneous 
injections of one of two different preparations of recombinant human erythropoietin 
(Eprex or Recormon) or 0.9 % saline. 
• Design: A double blind, placebo controlled, randomised crossover study. 
• Setting: Haemodialysis centres in two Dutch general hospitals. 
• Patients: Thirty-two haemodialysis patients regularly receiving subcutaneous 
erythropoietin to correct the anaemia of end-stage renal disease. 
• Intervention: Randomised subcutaneous injection of one mL of Eprex, Recormon, 
and saline in the outer part of the upper arm, at intervals of one hour. 
• Main outcome measures: A visual analogue scale with no divisions and a six 
point verbal descriptive scale were used by the patients to define grades of pain 
after each injection. 
• Results: The median percentage score on the visual analogue pain scale was 
significantly higher after injection of Eprex (35 %, interquartile range 13 to 51 %) 
than after injection of Recormon (0 %, 0 to 1 %) , or 0.9 % saline (0 %, 0 to 7 %) . 
Also the proportion of patients having had 'very mild' or 'no pain' on the verbal 
descriptive scale, was low with Eprex (0 .31 , 95 % confidence interval 0.16 to 
0.50) when compared to Recormon (0.97, 0.84 to 0.99) or saline 0.9 % (0 .81 , 
0.68 to 0.95). 
• Conclusion: Pain experienced after subcutaneous injection of recombinant 
human erythropoietin depends on the formulation of the solution. 
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Intravenous administration of recombinant human erythropoietin is effective for 
treating the anaemia of chronic renal failure (1,2). Subcutaneous erythropoietin is also 
effective (3). Moreover, it seems that the dosage requirements for subcutaneous 
administration may be lower than those of intravenous maintenance therapy (4). 
Subcutaneous administration is a convenient way of giving erythropoietin, 
particularly in pre-dialysis patients and patients receiving peritoneal dialysis. Self-
administration at home is feasible. However, after subcutaneous injection of Eprex 
(Cilag, Belgium) several of our patients reported unexpected pain at the injection site, 
which occasionally precluded self-administration. 
We report the results of a double blind, placebo controlled, randomised crossover 
study, designed to assess differences between pain experienced after subcutaneous 
injection of one of two different erythropoietin preparations or saline 0.9 %. 
Patients, Methods, and Results 
In two haemodialysis centres all adult patients regularly receiving subcutaneous 
erythropoietin (n = 32) were invited to participate in the study. Two brands of 
erythropoietin were tested: Eprex (aqueous solution of 1 mL containing 2000 U/mL 
erythropoietin (epoetin alpha), and 2.5 mg/mL human serum albumin in a citrate 
buffer) and Recormon (2000 U erythropoietin (epoetin beta) as a lyophilisate, then 
made up to 1 mL with water: Boehringer Mannheim, The Netherlands). Saline 0.9 % 
(Braun Melsungen, Germany) served as a placebo and control. Since in each of the 
centres all patients had been receiving either Eprex or Recormon they had not had the 
opportunity to compare both preparations with regard to pain. The solutions were 
equilibrated at room temperature before injection. 
At intervals of one hour the one-mL injections were given subcutaneously in the 
outer part of the upper arm by an experienced nurse. The sequence of the injections 
was randomised and blinded for both patient and nurse. 
A visual analogue scale with no divisions and a six point verbal descriptive scale 
were used by the patients to define grades of pain after each injection (5). The end 
points of the 15 cm vertical line on the visual scale were 'no pain at all' and 'pain as 
bad as it could be'. The horizontal verbal descriptive scale offered alternatives ranging 
from 'no pain' to 'very severe pain'. The table shows that the median percentage score 
on the visual scale was higher after injection of Eprex than after injection of 
Recormon or saline. The proportion of patients having had 'very mild' or 'no pain' 
on the verbal scale, was low with Eprex (0.31, 95 % confidence interval 0.16 to 0.50) 
when compared to Recormon (0.97, 0.84 to 0.99) or saline (0.81, 0.68 to 0.95). 
There was no significant difference between the scores of Recormon and saline. 
In a separate questionnaire the patients were asked which injection was most painful. 
Five patients had felt no pain after each of the three injections. Twenty-six of the 
remaining 27 patients indicated Eprex, and one indicated saline. 
There were no differences in pain scores between patients from the two 
haemodialysis centres if they were classified according to the regular use of Eprex or 
Recormon. 
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Percentage Scores for Pain on Visual Analogue Scale and Response on Verbal 
Descriptive Pain Scale after Subcutaneous Injection of Eprex, Recormon, or Saline 
Eprex Recormon Saline 
Visual analogue scores, %. 
Median (second and third quartiles) 35 (13, 51)* 0 (0, 1) 0 (0, 7) 
Range 0 - 9 0 0 - 1 7 0 - 3 3 
Verbal descriptive scale­
no (№) with very mild or no pain 31.3(10)* 96 9(31) 81.3(26) 
% (№) with mild to very severe pain 68.7 (22) 3.1 (1) 18 7 (6) 
* Ρ < 0 0001 for difference between Eprex and Recormon or saline, by signed rank test for visual 
analogue scale and McNemar"s test for verbal descriptive scale 
Comment 
The results show that pain after subcutaneous injection of erythropoietin is typically 
associated with Eprex. The pain was usually described as burning or itching, and was 
different from the pain occasionally felt after saline or Recormon. In most patients the 
pain had disappeared after 10 minutes. 
The absence of pain after subcutaneous injection of Recormon suggests that the 
inactive ingredients of the Eprex formulation are the cause of the pain. Further study 
is needed to elucidate whether the citrate buffer or perhaps human serum albumin in 
the Eprex solution is involved in this troublesome phenomenon. 
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Abstract 
• Background: Subcutaneous administration of epoetin alpha preparations may 
cause pain at the injection site. 
• Objective: To assess differences in pain experienced after subcutaneous 
injection of an epoetin alpha solution and its vehicle in patients. The vehicle and 
its component parts, albumin and citrate, were also compared in volunteers. 
• Design: Two double blind, placebo controlled, randomised order, crossover 
studies. 
• Setting: University hospital and haemodialysis wards of four teaching hospitals. 
• Subjects: Thirty-six chronic renal failure patients in the study containing the 
active drug, and 36 volunteers in the second study. 
• Interventions: Randomised subcutaneous administration of one mL of an epoetin 
alpha formulation, the vehicle, and its component parts. Normal saline served as 
a placebo control. 
• Main outcome measures: Scores obtained from visual analogue pain scales with 
no divisions and from five point verbal descriptive pain scales. 
• Results: Both the epoetin alpha solution and its vehicle caused significantly more 
pain than normal saline (P < 0.0001 ) in the patients studied. In volunteers the pain 
scores with the vehicle or its citrate component were significantly higher 
[P < 0.0001 ) when compared to normal saline or to the albumin component of the 
vehicle. 
• Conclusions: The local pain experienced after subcutaneous administration of 
epoetin alpha preparations is mainly caused by the citrate component of the 
buffered solution. Epoetin alpha and the albumin component of the preparation do 
not play a role in this phenomenon. 
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The treatment of the anaemia of chronic renal failure with recombinant human 
erythropoietin (epoetin, r-HuEPO) is now well established. Intravenous administration 
of the drug has been the principal route in the earliest studies involving mainly 
haemodialysis patients. However, this route is clearly impractical for regular use in 
outpatients treated with continuous ambulatory peritoneal dialysis and in pre-dialysis 
patients. Subcutaneous administration of epoetin is more convenient, and is suitable 
for self-administration at home. In addition, dose requirements are lower when 
compared to the intravenous route, even in haemodialysis patients (1). Therefore, 
subcutaneous administration of epoetin is widely accepted as the preferred route. 
However, local pain at the injection site is a common adverse event (2), sometimes 
precluding self-administration (3). Preparations of epoetin alpha cause significantly 
more pain when compared to preparations containing epoetin beta (3, 4). Epoetin 
alpha and epoetin beta are recombinant human erythropoietin products from two 
independent manufacturers, and do not show major differences. Yet, the two drugs 
differ in their formulation excipients. Epoetin alpha is diluted in an aqueous solution 
containing sodium chloride, citrate buffer, and human serum albumin. The latter two 
substances are not present in epoetin beta solutions. 
We report the results of two studies aimed to determine the substance in epoetin 
alpha solutions which is responsible for the pain after subcutaneous injection. In the 
first study, which included chronic renal failure patients, we examined whether epoetin 
alpha itself plays a major role. The second study included volunteers and examined 
the component parts separately. Both studies were designed as a double blind, 
randomised crossover study. Normal saline served as an inert placebo. 
Subjects and Methods 
First study. Thirty-six adult chronic renal failure patients in five haemodialysis 
centres were asked to participate in the study. The patients were all treated with 
epoetin alpha (Eprex, Cilag N.V., Brussels, Belgium), but had never received the drug 
via the subcutaneous route. Individuals suffering from chronic pain disorders, 
receiving analgesic therapy, or regularly using subcutaneous injections were excluded. 
After oral informed consent was obtained, age, weight, duration of haemodialysis and 
of epoetin therapy, skinfold thickness at the injection site, and current drug treatment 
were recorded. The study was designed to examine differences in pain experienced 
after subcutaneous injection of three different solutions, at a fixed volume of one mL. 
The three solutions tested were Eprex, Eprex-placebo (both provided by Cilag N.V., 
Brussels, Belgium), and saline 0.9 % (B. Braun Melsungen A.G., Melsungen, 
Germany). Eprex contained 4000 U/mL epoetin alpha, and 2.5 mg/mL human serum 
albumin. The buffered solution was composed of sodium chloride, citrate buffer, and 
water for injection. Eprex-placebo was identical to Eprex, except that it did not 
contain epoetin alpha. 
Second study. To assess which of the component parts of the Eprex formulation, 
human serum albumin or citrate buffer, causes pain following subcutaneous injection, 
a study including 36 healthy volunteers was done. The study was approved by the 
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local Hospital Ethics Committee, and written informed consent was obtained from the 
participants. Eprex-placebo and saline 0.9 % are described in the previous section. A 
sterile aqueous solution of 2.5 mg/mL human albumin was obtained by diluting 
Albuminar®-25 (Armour Pharmaceutical Company, Kankakee, Illinois, USA) in 
normal saline. This brand of albumin is also used in Eprex. Sodium citrate 0.58 % 
and citric acid 0.0057 % in sterile water were used as the component parts in the 
citrate solution, their concentrations being identical to those in Eprex. The osmolality 
of both the albumin and citrate solution was adjusted with saline to be identical with 
Eprex-placebo. The solutions were prepared by the Hospital Pharmacy of the 
University Hospital Nijmegen. The pH was identical in all solutions. 
The solutions were allowed to equilibrate at ambient room temperature before being 
prepared and injected. Standard disposable polypropylene syringes and 0.4 x 12 mm 
needles were used. A single experienced study nurse gave the injections by standard 
subcutaneous injection technique. All subjects received one mL of each solution 
subcutaneously alternating in the outer part of the upper arms. The order of the 
solutions to be injected was randomised, and both the nurse and the study subjects 
were blinded to their identity. 
Two pain scales were used by the patients and volunteers to assess the pain after the 
injection (5). These included a visual analogue scale (VAS), a 10 cm vertical line 
without gradations, and a verbal descriptive scale (VDS), five horizontally placed 
boxes with adjacent descriptors. The end points of the VAS ranged from 'no pain' (0 
cm) to 'pain as bad as it could be' (10 cm). The categories of the VDS were: 'no 
pain', 'mild pain', 'moderate pain', 'severe pain', and 'unbearable pain'. Following 
each of the injections, the two pain scales, of which the randomised sequence was 
blinded for the nurse, were separately marked by the participant as explained to him 
previously. 
The differences in VAS scores for pain were analysed with the signed rank test. The 
proportions of patients and volunteers who replied 'no pain' or 'mild pain' on the 
VDS, were compared by McNemar's tests. Spearman correlation coefficients were 
calculated to compare the pain scores on VAS and VDS, and to look for correlations 
of age, body weight, skinfold thickness, and duration of haemodialysis therapy with 
pain scores. For each formulation the Kruskal-Wallis test and Wilcoxon test were used 
to analyse differences in pain scores according to sequence number of the injections 
or sequence number of the pain scales. Differences were considered significant at the 
0.05 level. 
Results 
First study. The main characteristics of the patients are given in Table 1. Thirty-four 
patients were treated with haemodialysis, and regularly received Eprex intravenously. 
One patient treated with continuous ambulatory peritoneal dialysis, and one 
pre-dialysis patient were new users of Eprex. 
The pain scores assessed by the VAS are given in Table 2. There was a significant 
difference in pain scores between injection of saline 0.9 % and Eprex or 
66 
Table 1. Characteristics of Patients and Volunteers 
Patients Volunteers 
N* of subjects 
Median (range) age, y 
Sex (Female/Male) 
Mean ± SD weight, kg 
Median (quartiles) skinfold thickness, mm 
Median (quartiles) months on dialysis (л = 35) 
36 36 
53.0(19.0,81.3) 28.9(17.6,53.3) 
20/16 24/12 
60.7 ± 13.4 70.3 ± 10.3 
7 (5, 11) not done 
2.5 (1.5, 9.6) not applicable 
Table 2. Pain Scores on Visual Analogue Scale (Maximum = 10 cm) and Response on 
Verbal Descriptive Scale after Subcutaneous Injection of Eprex, Eprex-Placebo, or 
Saline 0.9 % 
Eprex Eprex-
placebo 
Saline 0.9 % 
Visual analogue score, cm 
Median (second and third quartiles) 2.7 (0.7, 4.5) 2.0 (0.2, 3.9) 0.0 (0.0, 0.7)* 
Range 0.0-8.3 0.0-9.0 0.0-3.0 
Verbal descriptive scale 
% (Na) with mild or no pain 52.8 (19) 63.9 (23) 94.4 (34)|,ф 
% (NB) with moderate to unbearable pain 47.2 (17) 36.1 (13) 5.6 (2) 
* Ρ < 0.0001 for difference between saline and Eprex or Eprex-placebo. 
t Ρ < 0.0001 for difference between saline and Eprex. 
% Ρ < 0.005 for difference between saline and Eprex-placebo. 
Eprex-placebo. The proportion of patients who marked 'mild' or 'no pain' on the VDS 
was also significantly lower with injection of saline 0.9 % (see Table 2). There was 
no difference between Eprex and Eprex-placebo. Within each group of solutions there 
was no relationship between pain experienced and age, sex, body weight, skinfold 
thickness at the injection site, or duration of dialysis or epoetin alpha therapy. 
In some patients (n = 3) an immediate erythema at the location of the injection of 
Eprex-placebo (n = 2) or Eprex (л = 2) was observed. The sharply demarcated 
erythema had a diameter of one to two cm and was irregular in shape. The erythema 
did not disappear during the observation period of four hours. The pain which was felt 
with Eprex or Eprex-placebo was described by most patients as burning or itching, 
and was different from the pain occasionally felt after the injection of saline. In most 
patients the pain had disappeared after 10 to 15 minutes. One patient who reported to 
have ingested 250 mg naproxen before the study and another patient on regular 5 
mg/day prednisone therapy did not differ in their pain scores when compared to the 
other patients. 
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Second study. The characteristics of the 36 healthy volunteers are given in Table 1. 
The pain scores assessed by the VAS after injection of Eprex-placebo or after injection 
of the citrate solution were significantly higher when compared to injection of the 
albumin solution or of normal saline (see Table 3). Similar results were obtained by 
the VDS, as regards the proportion of volunteers scoring 'moderate' to 'unbearable' 
pain (see Table 3). There was no difference in pain scores between Eprex-placebo and 
the citrate solution, nor between the albumin solution and normal saline. Adverse 
events did not occur during the study. No correlation was found between the scores 
on the VAS or VDS and body weight or age. 
In both studies no influence of the sequence number of the pain scales on the scores 
on VAS and VDS could be observed. Also, there was no influence of the sequence 
number of the injected solution on the scores on VAS or VDS. However, in 
volunteers the pain scores after injections of saline tended to be higher when saline 
was given as the first injection, when compared to the pain scores when saline was 
given as the last injection (P = 0.04). The mean Spearman correlation coefficient for 
VAS and VDS, according to solution injected, was 0.83 ± 0.03. 
Discussion 
Differences in pain sensation after subcutaneous injection between epoetin alpha and 
epoetin beta preparations suggested that the inactive ingredients of the epoetin alpha 
formulation are involved in this phenomenon. However, one study reported that the 
epoetin beta solution was even less painful than 0.9 % saline, which served as an inert 
placebo (4). The authors suggested the presence of an anaesthetic substance in this 
preparation. Therefore, a potential role of epoetin itself had not been ruled out. The 
results of our first study show that the epoetin alpha formulation causes significantly 
more pain than the relatively inert saline solution. The observed percentage pain 
scores are similar to those found in other studies (3, 4). In addition, the results 
confirm the hypothesis that epoetin alpha itself does not contribute highly to the degree 
of pain after subcutaneous injection of its solvent. 
In order to identify the pain-causing factor in the epoetin alpha solution, a second 
study was done, in which the inactive ingredients of the preparation were directly 
compared. This study demonstrates a similar distribution of pain scores for the epoetin 
alpha vehicle and the citrate solution. The injection of the solution containing albumin, 
which was of the same brand as used in Eprex, did not cause more pain than the 
injection of normal saline. The observed differences substantiate that local pain after 
subcutaneous injection of epoetin alpha solutions is mainly caused by the citrate buffer 
contained in the vehicle. 
There are no reports on the effects of long-term subcutaneous administration of 
preparations containing citrate buffers. The erythematous reaction seen in some 
patients suggests that the injection of epoetin alpha causes a local inflammatory 
response. This raises the question of chronic inflammatory changes at the injection 
sites after long-term use. However, it is reassuring in this regard that the current 
wide-spread experience with subcutaneous Eprex has not revealed harmful effects. 
69 
Currently only single-use vials of epoetin are available, which all have a volume of 
one mL. Due to the costs of epoetin, dosing regimens are often based on the 
prescription of whole vials. Therefore, in our studies a standard injection volume of 
one mL was used. Vials with different concentrations of epoetin alpha all contain the 
same concentration of inactive ingredients It is possible that the degree of pain is 
related to the amount of citrate buffer injected. If so, the pain problem might be 
reduced by using the currently available one mL vials with high concentrations of 
epoetin alpha, allowing for the injection of volumes of 0.1 to 0.2 mL. However, in 
order to keep such a therapy practical and cost-effective the development of 
multiple-dose vials or low-volume single-use vials of higher concentrations is required. 
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Abstract 
• Background: Pain at the injection site with subcutaneous administration of 
epoetin alpha preparations ¡s a common adverse event, and sometimes precludes 
self-administration. The pain is mainly caused by the vehicle. 
• Objective: To assess whether pain after subcutaneous administration of the 
vehicle can be influenced by making the solution ¡so-osmotic, or by diluting the 
vehicle by the bacteriostatic agent benzyl alcohol saline (BAS). The volumes 
injected were 1 mL. We also determined whether reduction of the injected volume 
of 1 mL to 0.33 mL o r to 0.1 mL could be of clinical importance. One mL of normal 
saline served as a placebo control in both studies. 
• Design: Two double blind, placebo controlled, randomised order, crossover 
studies. 
• Setting: University hospital. 
• Subjects: Two groups of 36 volunteers. 
• Interventions: Randomised subcutaneous administration of the vehicle for 
epoetin alpha, the vehicle diluted with BAS, and an ¡so-osmotic vehicle. Different 
volumes of the vehicle for epoetin alpha were also tested. Normal saline served as 
a placebo control. 
• Main outcome measures: Scores obtained from visual analogue pain scales with 
no divisions and from five point verbal descriptive pain scales. 
• Results: Dilution of the vehicle with BAS resulted in significantly less pain 
(P < 0.0001) after subcutaneous injection, comparable to levels obtained with 
normal saline. Making the vehicle iso-osmotic had no effects. Injection of smaller 
volumes of the vehicle was beneficial with 0.1 mL (P < 0.0001), but the reduction 
to 0.33 mL was not statistically significant. 
• Conclusions: Local pain after subcutaneous injection of the vehicle for epoetin 
alpha can be reduced by injecting small (0.1 mL) volumes. Moreover, dilution of the 
vehicle wi th the bacteriostatic agent BAS completely abrogates the pain 
sensations. 
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The anaemia of chronic renal failure can be successfully treated with recombinant 
human erythropoietin (epoetin, r-HuEPO). Subcutaneous self-administration of the 
drug is now appreciated as amenable for home use. Treatment with epoetin results in 
a significant improvement in quality of life, mainly due to better cardiovascular 
function and exercise tolerance. These beneficial effects are the main incentive for 
patient compliance. However, the therapy is not essentially vital and the drug does not 
exert acute effects. As a consequence, patient compliance during home use of epoetin 
is relatively more liable to be compromised. Strict adherence to the prescribed 
regimen is not easy to monitor. An important factor that influences patient compliance 
is the local tolerance of substances injected subcutaneously. 
Subcutaneous injections of one mL of preparations containing epoetin alpha cause 
substantially more pain than injections of normal saline, in a reproducible way (1-3). 
The pain is mainly caused by the citrate buffer contained in these solutions (3). 
Although the pain is transient, lasting 10 to 15 minutes, and is acceptable for most 
patients, it sometimes precludes self-administration. These observations prompted us 
to investigate potential measures to reduce the pain associated with these injections. 
More concentrated solutions of epoetin alpha (10 000 U/mL) are now becoming 
widely available, and they do not differ from less concentrated solutions as regards the 
concentration of the citrate buffer. These solutions allow for using lower volumes to 
be injected. Therefore, we compared the effects of different volumes on pain 
experienced after subcutaneous injection. Since the pain is caused by the vehicle for 
epoetin alpha, this solution was used, and could be studied in volunteers. One mL 
vials with concentrated solutions of epoetin must be suitable for multiple use to remain 
cost-effective. Preparations marketed in multiple-dose vials require the presence of a 
bacteriostatic agent. Therefore, we also investigated whether dilution of the vehicle 
for epoetin alpha with the commonly used bacteriostatic agent benzyl alcohol saline 
(BAS) had effects on pain. 
Subjects and Methods 
Two studies were done to examine measures to reduce pain after subcutaneous 
injection of Eprex-placebo, the vehicle for epoetin alpha (Eprex: Cilag N.V., Brussels, 
Belgium). Both studies were designed as a double blind, randomised, crossover study. 
Normal saline served as an inert placebo. Each study included 36 volunteers. The 
studies were approved by the local Hospital Ethics Committee, and written informed 
consent was obtained from the participants. Age, weight, and skinfold thickness at the 
injection site were recorded. 
In the first study the influence of the addition to Eprex-placebo of benzyl alcohol 
saline, a bacteriostatic agent used as drug diluent, was examined. The reference 
solutions tested were Eprex-placebo, and saline 0.9 % (B. Braun Melsungen A.G., 
Melsungen, Germany). The buffered Eprex-placebo solution was composed of sodium 
chloride, citrate buffer, and water for injection, and contained 2.5 mg/mL human 
serum albumin. Eprex-placebo is identical to Eprex, except that it does not contain 
epoetin alpha. The preparation containing BAS (Eprex-placebo-BAS) was prepared by 
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adding to one mL of Eprex-placebo, 1.5 mL of a solution containing 9 mg/mL sodium 
chloride and 9 mg/mL benzyl alcohol (Abbott Laboratories, North Chicago, Illinois, 
USA). So, the final osmolality of Eprex-placebo-BAS at injection would be 323 
mosmol/L. However, since benzyl alcohol is not osmotically active in vivo, the 
effective osmolality of Eprex-placebo-BAS is considered to be 270 mosmol/L. The 
concentrations of the citrate buffer and albumin in Eprex-placebo-BAS are reduced to 
40 % of the original Eprex-placebo solution. The osmolality of Eprex was found to 
be 243 ± 3 mosmol/L, whereas the osmolality of saline 0.9 % was 289 ± 1 
mosmol/L. To exclude a possible influence of the higher tonicity of the 
Eprex-placebo-BAS solution when compared to Eprex-placebo, a fourth solution with 
more physiological osmolality was used as a control. This solution 
(Eprex-placebo-saline) was prepared by adding 0.1 mL of saline 3 % (Hospital 
Pharmacy, University Hospital Nijmegen, The Netherlands) to one mL of 
Eprex-placebo, resulting in an osmolality of 300 mosmol/L and in only a small 
dilution of the other inactive ingredients citrate and albumin. 
In the second study we assessed whether the pain following subcutaneous injection 
of Eprex-placebo can be reduced by lowering the volume injected. All volunteers 
received four injections: three Eprex-placebo injections of different volumes and one 
injection of saline 0.9 %. The volumes of the Eprex-placebo injections were 1.0,0.33, 
and 0.1 mL, respectively. Saline was given in a volume of 1 mL. 
The study solutions were allowed to equilibrate at ambient room temperature before 
being prepared and injected. Standard disposable one mL polypropylene syringes and 
0.4 x 12 mm needles were used. A single experienced study nurse gave each injection 
by standard subcutaneous injection technique. The order of the solutions was 
randomised, and both the nurse and the study subjects were blinded to their identity. 
Due to differences in length of the outer part of the plunger, related to differences in 
volume, in the second study only the volunteers could be blinded for the syringes 
used. All solutions were slowly injected during a similar period of time, regardless of 
the volume injected. The injections were given at least 45 minutes apart. All subjects 
received one mL of each solution subcutaneously alternating in the outer part of the 
upper arms. 
Two pain scales were used by the patients and volunteers to assess the pain of the 
entire injection (4). These included a visual analogue scale (VAS), a 10 cm vertical 
line without gradations, and a verbal descriptive scale (VDS), five horizontally placed 
boxes with adjacent descriptors. The end points of the VAS ranged from 'no pain' (0 
cm) to 'pain as bad as it could be' (10 cm). The categories of the VDS were: 'no 
pain', 'mild pain', 'moderate pain', 'severe pain', and 'unbearable pain'. Following 
each of the injections, the two pain scales, of which the randomised sequence was 
blinded for the nurse, were separately marked by the participant as explained to him 
previously. In the second study the volunteers also noted the duration of the pain. 
The differences in VAS scores for pain were analysed with the signed rank test. The 
proportions of volunteers who replied 'no pain' or 'very mild pain' on the VDS were 
compared by McNemar's tests. Spearman correlation coefficients were calculated to 
compare the pain scores on VAS and VDS, and to look for correlations of age, body 
weight, and skinfold thickness with pain scores. For each formulation the 
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Table 1. Characteristics of Volunteers 
Study 1 Study 2 
№ of subjects 36 36 
Median (range) age, y 26.6 (20.3, 52.5) 24.0 (19.6, 43.7) 
Sex (Female/Male) 14/22 21/15 
Mean ± SD weight, kg 70.0 ± 10.2 67.5 ±11.0 
Median (range) skinfold thickness, mm 11.0(5,34) 12.5(4,31) 
Kruskal-Wallis test and Wilcoxon test were used to analyse differences in pain scores 
according to sequence number of the injection. Differences were considered significant 
at the 0.05 level. 
Results 
The characteristics of the participating volunteers of both studies are given in Table 
1. In the first study the volunteers experienced more pain after injection of 
Eprex-placebo when compared to saline 0.9 % {see Table 2). Dilution of 
Eprex-placebo with BAS gave a considerable reduction of pain to levels comparable 
to saline 0.9 %. Correction of the osmolality of Eprex-placebo with saline 3 % 
(Eprex-placebo-saline) did not lead to improvement in the pain scores. These results 
were confirmed by the results of the scores on the VDS {see Table 2). 
In the second study the volunteers experienced significantly less pain after injection 
of 0.1 mL of Eprex-placebo when compared to 0.33 mL or 1 mL of Eprex-placebo 
{see Table 3). Although the values obtained with 0.33 mL were intermediate to those 
of 1.0 and 0.1 mL, the difference with 1.0 mL was not statistically significant. Pain 
scores after 0.1 mL of Eprex-placebo were somewhat higher than after 1 mL of saline 
0.9 %. The scores on the VDS gave similar results {see Table 3). The proportions of 
subjects scoring 'no pain' or 'mild pain' on the VDS did not differ between 0.1 mL 
of Eprex-placebo and 1 mL of saline {see Table 3). However, the proportion of 
subjects who marked 'no pain at all' on the VDS was still significantly higher 
(P = 0.04) with saline (36.1 %) than with 0.1 mL of Eprex-placebo (13.9 %). 
Compared to 1 mL of Eprex-placebo, also the duration of the pain was shorter with 
injection of 0.1 mL, but not with 0.33 mL {see Table 3). The mean duration of pain 
with 1 mL saline was slightly shorter than with 0.1 mL of Eprex-placebo. 
Within each group of solutions there was no relationship between pain scores and 
age, sex, body weight, or skinfold thickness at the injection site. There was also no 
influence of the sequence number of the injections or of the pain scales on the scores 
on the VAS or VDS. The osmolality of the solutions in the first study was measured 
and they were as predicted: Eprex-pIacebo-BAS 323 ± 1, saline 289 ± 2, 
Eprex-placebo 245 + 2, and Eprex-placebo-saline 309 ± 4 mosmol/L. However, as 
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can be expected from the results with the VAS and VDS pain scores, no correlation 
was found between osmolality and pain scores. There was a good correlation (mean 
r = 0.79 ± 0.07) between the pain scores on the VAS and the VDS for each solution 
tested. No adverse events occurred during the studies. 
Discussion 
After having identified the citrate buffer in the vehicle for epoetin alpha as the pain 
causing factor (3) we were interested to find measures to reduce pain associated with 
subcutaneous injection of epoetin alpha. Improvement of the local tolerance of the 
drug might prevent a potential decline in patient compliance. Good patient compliance 
is essential for long-term home use of this drug. In this study we show that dilution 
of the vehicle with appropriate amounts of a solution containing the bacteriostatic 
agent BAS, results in reduction of pain to levels comparable to those experienced with 
injection of normal saline. The observed effect of BAS might be brought about by 
dilution of the vehicle. However, it is more likely that the local-anaesthetic properties 
of BAS are the explanation for its efficacy (5, 6). BAS is commonly used as a 
bacteriostatic agent in many medications and fluids for parenteral administration, 
usually in a concentration of 0.9 % (7). It appears to be relatively safe for 
small-volume parenteral administration in adults (8,9). The drug rarely causes contact 
dermatitis (6, 7). In this study BAS was used in a concentration that provides a lesser 
antimicrobial effect, and this concentration is not expected to be suitable for multiple 
use. Yet, it is conceivable that normal concentrations of BAS will be at least equally 
effective. Therefore, our results demonstrate that when solutions containing BAS are 
used, its additional anaesthetic properties should be taken into account. 
In the second study we showed that a significant reduction in the intensity of pain 
could be achieved by reducing the volume of the vehicle to 0.1 mL, but with 0.33 mL 
the reduction was not statistically significant. Also, the duration of the pain was 
significantly shorter. These results suggest that the majority of patients can be treated 
without excess pain at the injection site by using low volumes of highly concentrated 
epoetin alpha solutions. 
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Erythropoietin (EPO) is a hormone that plays an essential role in the regulation of red 
blood cell development (1). There is firm evidence that the kidney is the major source 
of EPO (2). Insufficient EPO secretion by the diseased kidney is the main cause of 
anaemia in patients with renal failure. Anaemia is a common complication of renal 
disease and results in reduced exercise tolerance, chronic fatigue, and decreased 
quality of life in most of these patients. These factors often limit their rehabilitation. 
Until recently, periodic erythrocyte transfusions constituted the mainstay for the 
treatment of anaemia of end-stage renal failure. However, blood transfusions are 
associated with important potential complications, including iron overload, 
transmission of infection, immunosuppression, and transfusion reactions. Also, in 
patients who receive blood transfusions antibodies to HLA antigens often develop, 
which may preclude successful transplantation. Substitution of exogenous EPO for 
insufficiently produced endogenous EPO was impossible since, unlike e.g. insulin, 
extraction of EPO from natural resources provided only minute amounts. Yet, recent 
advances in recombinant DNA technology have led to the production of large 
quantities of recombinant human erythropoietin (r-HuEPO, epoetin). R-HuEPO is 
indistinguishable from native EPO by immunological or biological techniques. The 
advent of r-HuEPO provided the basis for rational substitution therapy in the treatment 
of anaemia associated with chronic renal failure. The need for transfusion therapy is 
eliminated by r-HuEPO, thereby avoiding its associated risks. Anaemia-specific 
physical symptoms will be alleviated substantially and subjective sense of well-being 
improves significantly. 
In this report we will discuss the different routes of administration of recombinant 
human erythropoietin (r-HuEPO). For better understanding, some aspects of the 
pharmacodynamics and pharmacokinetics of r-HuEPO will be pointed out. The 
consequences for practical therapy will be summarized. 
Pharmacodynamics 
The available evidence, although not conclusive, favours the concept that interstitial 
cells in proximity to tubules in the renal cortex and in the adjacent outer renal medulla 
produce EPO. Our understanding of the link between reduced oxygen supply to the 
tissues and the synthesis of EPO in the kidney is still poor, whereas the exact 
mechanisms for the control of EPO production are also unknown. 
The maturation of haematopoietic progenitor cells proceeds from primitive 
pluripotent haematopoietic stem cells to lineage-restricted progenitor cells that are 
destined for terminal differentiation. The action of EPO is almost exclusively limited 
to the growth of erythroid precursor cells. The cells within the erythroid lineage that 
are stimulated by EPO are defined operationally as erythropoietin-responsive cells 
(ERC). This population of ERC includes two major subpopulations: the erythroid 
burst-forming unit (BFU-E) which differentiates into the erythroid colony-forming unit 
(CFU-E). The maturation from BFU-E to CFU-E progresses with an increasing 
sensitivity to EPO. The pluripotent stem cell on one side and erythroblasts on the 
other side are both not affected by EPO. Erythroid progenitor cells respond to a 
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variety of growth and development promoting factors produced in their micro-
environment, but only EPO is obligatory in vivo for terminal differentiation. EPO acts 
synergistically with interleukin-3 (IL-3) and granulocyte/macrophage colony-
stimulating factor (GM-CSF) to expand the BFU-E compartment. It also seems to 
stimulate the early release of reticulocytes from bone marrow into the circulation. 
BFU-E and CFU-E are present in the human bone marrow at a very low frequency 
of 0.1 to 1.0 %. This explains why it is difficult to do studies of EPO receptors using 
purified normal haematopoietic tissues. Yet, homogeneous populations of enriched 
murine erythroid cell lines that respond to EPO could be generated. In addition, some 
erythroleukaemia cell lines showed a growth dependency on EPO in culture. Cross-
linking studies with 125I-r-HuEPO involving these cell populations have shown that 
EPO combines with specific binding sites on the cell surface in a typical hormone-
receptor interaction (3). The number of EPO receptors on the cell surface is relatively 
small, about 800 to 1200 per cell, and appears to vary with maturation stage. Some 
studies show the existence of two classes of binding sites on erythroid progenitor cells, 
a high affinity and a low affinity EPO receptor. Different cells either contain both 
receptor classes or generally the low affinity receptor only. Although the only known 
physiological action of EPO is on erythroid tissue, the presence of EPO receptors on 
other cells has also been reported in animals. The demonstration of low affinity EPO 
receptors on human megakaryocytes might partly explain some increase in 
thrombocyte counts after intravenous injection of EPO in patients with renal failure. 
The high affinity receptor seems to be essential for erythroid differentiation in 
response to EPO, since cells lacking this receptor generally do not differentiate in 
response to EPO. Moreover, given its physiological concentrations in serum, in vivo 
EPO would occupy only the high affinity receptor and then only partially. In vitro, 
purified murine CFU-E show a rapid turnover of the high affinity receptors (4). Low 
affinity sites persist for a much longer time and at a larger number. As few as eight 
to 10 EPO molecules appear to be sufficient to initiate colony formation by CFU-E. 
However, the rapidly turning over EPO receptors must be continuously occupied for 
this to occur (4). The often large amount of EPO already internalised into the cell 
cannot satisfy the almost absolute need for EPO in the early stage of in vitro growth 
by CFU-E. Thus, a more or less continuous presence of EPO is necessary in in vitro 
culture systems to maintain the development, maturation and differentiation of red 
cells. This is also in keeping with results of the in vivo bioassay of EPO where the 
biological effect of a given dose EPO was largest when it was administered 
intermittently in divided gifts. These findings might explain some of the complex 
therapeutic properties r-HuEPO exhibits. They will be discussed later in this article. 
Internalisation of EPO appears to be unnecessary for its action, but the detailed 
initial sequence of biochemical postreceptor signal transduction, mediating the effects 
of EPO, remains to be determined. These processes probably will be better understood 
when the EPO receptor will have been isolated, purified and characterised. The later 
events that occur as the erythroid progenitor cells mature into late erythroblasts have 
been described (1), but their role is still undefined. At the cellular level EPO induces 
an increase in cytosolic Ca2+ within one minute. The hormone is present in the cell 
by 10 to 30 minutes where it undergoes lysosomal degradation. The fate of the EPO 
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receptor is unknown but recent studies support the hypothesis that it is degraded, and 
upregulation of the receptor occurs by de novo synthesis. Total RNA synthesis 
increases due to the activation of transcription within three to four hours and is 
followed by protein and DNA synthesis. After six hours a and ß globin gene 
transcription rates increase, with a concomitant increase in the number of transferrin 
receptors. A marked haemoglobin synthesis follows within 12 hours. 
Pharmacokinetics 
To produce its characteristic effects a drug must be present in appropriate 
concentrations at its sites of action. Although obviously a function of the amount of 
drug administered, the concentrations attained also depend upon the extent and rate of 
its absorption, distribution, biotransformation and elimination. The pharmacokinetics 
of single doses of r-HuEPO have been studied in small groups of patients on 
haemodialysis and on С APD, and in pre-dialysis patients and healthy volunteers. In 
these studies the intravenous (IV), subcutaneous (SC) and intraperitoneal (IP) routes 
of administration were investigated. 
Unless large concentrations of r-HuEPO are used, after IV injection the plasma 
concentration profile of the hormone in humans is best described by a bi-exponential 
curve with an initial rapid distribution phase and a slower elimination phase (5). In 
most studies the apparent volume of distribution was equal to or up to twice the 
plasma volume. Distribution studies in animals reveal that most uptake of r-HuEPO 
occurs in the liver, kidney, and spleen. However, specific uptake occurs mainly in the 
bone marrow (6). The liver is considered the most likely site of r-HuEPO degradation, 
but the bone marrow may make a significant contribution. The precise size of the 
contribution of the bone marrow to r-HuEPO clearance at physiological plasma levels 
will remain uncertain until equilibrium studies, measuring total turnover of r-HuEPO 
in the bone marrow, will have been done. 
Following IV administration of r-HuEPO, plasma concentrations reach a high peak 
shortly after the injection. The elimination half-life of IV r-HuEPO ranged between 
6 and 12 hours (mean 9.3 + 3.2) in 11 haemodialysis patients (7). This was 
comparable with the mean plasma half-life of r-HuEPO in С APD patients, being 8.2 
hours (range 6.2 to 10.2) (8). In another study the elimination half-life of IV r-HuEPO 
ranged from 2.3 to 7.3 hours (9). These different results can be explained by the great 
interindividual variations of r-HuEPO elimination together with the small numbers of 
patients that have been investigated. However, small differences in glycosylation 
between the r-HuEPO molecules of the various commercial preparations are likely to 
result in differences in pharmacokinetic profile (10). Some investigators noted a 
decrease in half-life after multiple IV injections (11). In haemodialysis patients treated 
with 500 U/kg intravenously the half-life decreased from 9.3 hours to 6.2 hours after 
seven injections in five of six patients (7). Similar effects were seen in pre-dialysis 
patients (12). On the first day of therapy the half-life was 7.7 hours, whereas on day 
54 it had decreased to 4.6 hours. However, other investigators reported no change in 
elimination half-life after repeated r-HuEPO dosing (9). It is unknown why these 
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differences exist, but antibodies are not involved. Endogenous EPO production is 
independent of the circulating EPO level (13), and in rats the plasma clearance of the 
hormone is also independent of its plasma concentration (6). In rats the rate of 
erythropoiesis does not seem to influence the plasma clearance of erythropoietin (14). 
After SC administration of r-HuEPO, plasma concentrations start to increase after 
two hours (5, 8, 9, 11). Peak concentrations are found at 12 to 18 hours and are of 
course much lower when compared to IV administration. Thereafter there is a gradual 
decline that is slower than the clearance of intravenously administered r-HuEPO. 
Measurable levels persist for up to 96 hours after SC injection compared to 36 to 48 
hours after IV administration. In one study the mean relative bioavailability of SC 
r-HuEPO, as measured by the area under the curve (AUC), was found to be 21.5 % 
(range 11.3 to 36.0 %) (8), whereas others found 49 % (range 23 to 79 %) (5). 
With IP administration to CAPD patients, increased concentrations of r-HuEPO are 
detectable within one to two hours (5, 8, 9). Plasma r-HuEPO values do not reach 
steady state levels due to the relatively short dwell times and the removal of r-HuEPO 
from the peritoneal cavity after the dwell. In many patients r-HuEPO absorption into 
the blood stream continued for some hours after rinsing of the peritoneal cavity, 
suggesting delayed transport of the hormone in the lymphatic system. However, 
thereafter elimination half-life was much shorter than after SC administration, and 
approximated the half-life obtained with IV r-HuEPO. The mean relative 
bioavailability of r-HuEPO after IP administration was 2.9 % (range 1.2 to 6.8 %) 
(8), and 6.8 % (range 2.2 to 12 %) in another study (5). Yet, r-HuEPO absorption 
from the peritoneal cavity increases when the concentration of r-HuEPO in the dialysis 
fluid is increased by using smaller volumes of dialysis fluid. Absorption increases also 
with longer dwell times. Thus, the results of the calculated AUC after IP 
administration strongly depend on the dialysis scheme used. 
Therapeutic Use 
Large multicentre trials have extended and confirmed the initial observations with 
r-HuEPO. Virtually all patients responded appropriately to r-HuEPO, and increased 
their haematocrit to the target range. The patients no longer needed transfusions and 
their quality of life improved. Patients have been receiving r-HuEPO for up to five 
years. Resistance to r-HuEPO has not been observed, neither have antibodies to the 
hormone been detected. 
The most important adverse effect with all routes of administration of r-HuEPO is 
an increase in blood pressure, in most cases necessitating institution or increase of 
antihypertensive therapy. The reported incidence of hypertensive complications is 
about 30 % (15). Preliminary analysis of the US and European experiences with 
r-HuEPO indicates that the development of hypertension is not related to the dose of 
r-HuEPO, nor are the final haematocrit achieved or the rate of increase in haematocrit 
clearly involved. However, those patients with more severe anaemia (haematocrit less 
than 0.20 L/L) appear to be at larger risk for the development of hypertension. 
Increases in blood pressure occur particularly during the first months of therapy, and 
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blood pressure usually stabilizes thereafter. Acute elevation in blood pressure during 
r-HuEPO therapy occasionally results in hypertensive encephalopathy and seizures. 
This complication is unrelated to the extent or rate of increase in haematocrit, and may 
occur also in previously normotensive patients. 
Hypertension is absent in anaemic patients without renal disease treated with 
r-HuEPO. This indicates that r-HuEPO by itself does not cause hypertension. The 
appearance of hypertension is probably related to the haemodynamic changes induced 
by correction of the anaemia (16). In haemodialysis patients there is a hypoxic 
peripheral vasodilation induced by the anaemia. When haematocrit increases during 
r-HuEPO-treatment, but also by blood transfusions, vasodilation decreases and 
peripheral resistance increases. During r-HuEPO treatment whole blood viscosity 
increases, which also can increase peripheral resistance. An increase in systemic 
vascular resistance occurs in all patients successfully treated with r-HuEPO, whether 
or not blood pressure increases. However, in patients in whom blood pressure 
increases there is a lack of adequate adaptive reduction of cardiac output, and this in 
turn may be due to abnormal cardiovascular autoregulation in these patients. Once the 
patients have been adjusted to their new haemodynamic status the risk of hypertensive 
complications is reduced. A slow increase in haematocrit allows time for these 
haemodynamic adaptations to occur, and for appropriate control of blood pressure. 
Expansion of the extracellular volume is the most important mechanism in the cause 
of the elevated blood pressure in haemodialysis patients. Since haemodialysis patients 
are unable to regulate their extracellular volume, blood pressure should carefully be 
controlled by appropriate dialysis ultrafiltration and with antihypertensive medication. 
Inflammation, infection, severe osteitis fibrosa associated with hyperparathyroidism, 
aluminium intoxication, deficiencies of iron, folate, or vitamin B12, haemolysis, and 
blood losses may blunt the response to r-HuEPO. This may occur also during the 
maintenance phase of r-HuEPO therapy. Inflammation and iron deficiency are the 
most common causes of an inappropriate or declining response during r-HuEPO 
treatment. Acute and chronic inflammatory disorders and large surgical procedures 
often decrease the efficacy of r-HuEPO temporarily, until these states have resolved. 
Increasing the dosage of r-HuEPO is generally ineffective, but r-HuEPO should not 
be withheld. An inadequate response to r-HuEPO may be due to inappropriately low 
body iron stores. A serum ferritin value of less than 50 μg/L is regarded as the 
threshold level for iron deficiency in chronic renal failure patients and this correlates 
well with bone marrow iron stores. Oral iron supplementation during several months 
before institution of r-HuEPO therapy may correct part of the anaemia in these 
patients. The amount of additional iron required during r-HuEPO treatment depends 
mainly on the magnitude of new haemoglobin synthesis. A massive transfer of iron 
from storage sites is required during r-HuEPO therapy. Iron depletion will result if 
body iron stores are inadequate to meet the needs for new haemoglobin synthesis, or 
if iron is not released appropriately. For patients with a ferritin level in excess of 1000 
μg/L, there would be no initial need for iron therapy during r-HuEPO therapy. 
However, those with a ferritin level between 50 and 500 μg/L ought to be on regular 
iron supplements (up to 200 mg of elemental iron per day) to prevent iron deficiency. 
Functional iron deficiency can occur at normal or elevated levels of serum ferritin. 
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Values of mean corpuscular volume (MCV) of erythrocytes < 80 fL, transferrin 
values > 50 μιηοΙ/L, or transferrin saturation < 20 % may be indicative. Also after 
correction of haemoglobin, iron supplementation may be needed to maintain the target 
haemoglobin. Therefore, at the start and during the correction phase of r-HuEPO 
therapy monitoring of serum ferritin should be performed at monthly intervals, and 
every three months once the target haemoglobin has been reached. 
Intravenous Administration 
In the first study in haemodialysis patients a dose finding protocol was used (17). IV 
r-HuEPO 15 U/kg three times a week was the minimum effective dosage. However, 
the rise in haematocrit was relatively slow. At a dosage of 50 U/kg IV three times a 
week, reticulocyte counts and haematocrit often increase within one to three weeks 
after the start of the therapy. Most patients no longer require transfusions after this 
time. The response to r-HuEPO showed a dose-dependency. Target haematocrit is 
achieved within four to six weeks with higher dosage regimens (up to 500 U/kg three 
times a week have been given intravenously) depending on the initial degree of 
anaemia. In the bioassay for EPO the production of red cells is a function of the 
logarithm of the dose. This implies that doubling the response will be possible only 
at the expense of very large doses of r-HuEPO. Apart from the questions about cost-
effectiveness that are raised by the use of high dosages, lower dosages of r-HuEPO 
are to be preferred, because a slow increase in haematocrit appears to cause less side 
effects. Clinical trials have shown that most patients require between 25 and 125 U/kg 
three times per week to maintain a stable haematocrit. A minority (± 25 %) of 
patients require 150 to 300 U/kg three times per week. 
The 'Statement on the Clinical Use of Recombinant Erythropoietin in Anemia of End 
Stage Renal Disease' by the 'Ad Hoc Committee for the United States National 
Kidney Foundation' recommends administration of IV r-HuEPO three times a week 
at a dose of 150 U/kg until the haematocrit reaches 0.30 L/L (18). The dose can then 
be decreased to 75 U/kg and should be adjusted up or down in amounts of 12.5 to 25 
U/kg until a dose is achieved that will maintain the haematocrit at about 0.35 L/L. 
However, in patients with unstable hypertension, they advise to use a lower initial 
dose (50 to 100 U/kg). These recommendations involve a rather high initial dose of 
r-HuEPO. Patients with relatively high haematocrits will not need high initial doses 
of r-HuEPO because they will reach and pass the 0.30 L/L level in a short period of 
time. Moreover, in patients with low haematocrit and patients with a history of 
hypertension (more than 30 %) high initial doses are hazardous. Since most of the 
remaining patients will respond to a low initial dose, a 'low and slow' dosing protocol 
is usual in Europe. Emphasis is placed on dose titration to achieve target haematocrit 
values. The recommended IV starting dose is 50 U/kg three times a week, adjusted 
by increments of 25 U/kg at six-weekly intervals, to achieve target haematocrit values 
within 12 to 18 weeks. 
88 
Subcutaneous Administration 
Bommer studied patients who had been receiving intermittent Г r-HuEPO three 
times a week for more than one year and then received r-HuEPO subcutaneously three 
times a week (19). In this first study, the SC dose could be reduced to 50 % of the 
IV dose without a decrease in the haemoglobin level. In a larger follow-up study he 
showed that the dose reduction was maintained at about 30 %. With SC r-HuEPO the 
relative bioavailability is only 20 to 50 % compared to IV. However, it results in a 
longer plasma half-life and consequently a more prolonged persistence of adequate 
plasma r-HuEPO levels. The difference in pharmacokinetic profiles seen after SC 
compared to IV administration is reflected in the increased clinical efficacy of this 
treatment modality. The before-mentioned studies on receptor kinetics may explain this 
phenomenon. So, moderate continuous stimulation of the bone marrow following SC 
injection is more effective than pulsatile stimulation after intermittent IV injection. 
Dose recommendations for SC r-HuEPO are still largely empirical. However, the 
recommended conventional starting dose is 25 to 50 U/kg, three times a week. 
Growing evidence attests to the simplicity and efficacy of a standard starting dose of 
one vial of 1000 or one vial of 2000 U three times a week for all adult patients, 
thereby avoiding drug wastage. Generally, the starting dose with SC administration 
should not exceed 50 U/kg, in order to avoid too rapid a rise in haematocrit. 
The incidence of hypertension appears to be the same with both SC and IV 
administration. The more acute adverse effects of IV r-HuEPO (such as 'flu-like 
syndrome', headache, bone and muscle pains), seem to occur less frequently with SC 
administration. In a minority of patients the SC application of certain r-HuEPO 
preparations results in a more or less short-lasting burning pain. This is the result of 
the properties of the buffered solution used. In these cases changing the preparations 
will relieve these local problems 
More studies, involving larger numbers of patients, are necessary to assess the 
benefits of SC dosing more precisely. However, the evidence already available 
suggests that SC administration of r-HuEPO is the optimal route for r-HuEPO. The 
maintenance dose can be reduced considerably, resulting in large cost-savings. 
Analysis of the current trials shows that the response to r-HuEPO in CAPD patients 
is not different from the response in haemodialysis and pre-dialysis patients. 
Moreover, SC dosing three times a week in CAPD patients will be far more 
convenient than IV dosing. 
Intraperitoneal Administration 
IP administration of r-HuEPO is still under investigation. The relative bioavailability 
of r-HuEPO is less than 10 % after IP administration when compared to IV. These 
data might suggest that in particular IP r-HuEPO would not be effective. However, 
in spite of low bioavailability values the therapeutic efficacy of SC r-HuEPO has 
already been proved. We investigated the therapeutic effectiveness of these treatment 
modalities. Patients on CAPD injected 100 U/kg of r-HuEPO subcutaneously (n = 8), 
or intraperitoneally in their dialysis bag (n = 9) three times a week. With r-HuEPO 
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added to the bag the dialysis volume was one litre and the glucose concentration was 
1.5 %. The dwell times were 10 to 12 hours during the night. In the SC group the 
rate of increase in haematocrit was twice the rate with IP r-HuEPO. However, with 
administration of r-HuEPO three times a week, the results in the IP group were 
comparable to the results in intravenously treated pre-dialysis patients, who were 
matched for initial haematocrit. Preliminary data from IP administration of r-HuEPO 
in a small volume of dialysis fluid in children treated with intermittent peritoneal 
dialysis show a therapeutic effect that is comparable to SC administration. 
Dosing Schedule 
Information on the optimal dosing schedule and the best route of administration is 
still incomplete. IV injections three times a week at the end of dialysis are convenient 
in haemodialysis patients, but are not the most cost-effective way of administration. 
Dosing once a week gives a sufficient response in most patients. Yet, Muirhead 
showed that this schedule requires larger doses than dosing three times a week (20). 
Moreover, Bommer showed that when r-HuEPO was given twice a week instead of 
three times, 30 % more r-HuEPO was needed (19). Dosing three times a week ensures 
a constantly elevated plasma r-HuEPO level. Dosing more frequently than three times 
a week does not yield any benefit, as was recently shown by the preliminary results 
from ongoing clinical trials involving large numbers of patients. These observations 
suggest that a continuous minimum plasma r-HuEPO level is required and this is in 
keeping with the earlier mentioned studies, which demonstrated that repeated 
occupancy of the rapidly turning over EPO receptors is required. 
It is still unknown what the optimal target value for the haematocrit should be. In 
most patients increasing the haematocrit till 0.32 to 0.35 L/L improves considerably 
the quality of life, and in particular exercise tolerance. There are no studies showing 
significant further benefits if the haematocrit is increased to more than 0.35 L/L. 
Moreover, this might result in increased difficulty in controlling blood pressure or an 
increased incidence of thrombotic complications in arteriovenous fistulae or clotting 
in the artificial kidney during haemodialysis. 
Conclusions 
In the last five years, the rapid development of modern biotechnological techniques 
made it possible to devise reliable assays for the determination of EPO, and to 
produce r-HuEPO on a large scale. Substitution therapy with r-HuEPO was rapidly 
introduced in nephrology and its place as an effective method to correct the anaemia 
of chronic renal failure is firmly established. However, the mechanisms whereby EPO 
production in the kidney is regulated are still not unravelled. Moreover, the complex 
actions of r-HuEPO on the red blood cell-forming cells are incompletely understood. 
In various studies it has appeared that descriptive pharmacokinetics alone do not 
appropriately predict the biological response to r-HuEPO. This is illustrated by the 
apparently better effectiveness of SC r-HuEPO when compared to IV, despite the 
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lower bioavailability of the former application. 
Further studies to investigate the optimum route of administration, the optimum 
target haematocnt, and the long term effects are required in the coming years. An 
increased understanding of the basic principles of the physiology and pathophysiology 
of EPO will emerge in this decade. 
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Summary and Conclusions 

Summary and Conclusions 
Promising results of the first studies with recombinant human erythropoietin 
(r-HuEPO, epoetin) in haemodialysis patients prompted us to participate in the clinical 
introduction of the hormone in the treatment of anaemic pre-dialysis patients. These 
are patients with end-stage renal failure who do not yet require dialysis. Special 
attention was paid to the effects of increasing haematocrit on renal function. The 
results of these studies form the first part of this thesis, including a discussion of the 
inferences from relevant publications. Initially r-HuEPO was administered 
intravenously, but obviously this is not the most convenient way to treat outpatients. 
Therefore, we studied the feasibility of subcutaneous and intraperitoneal administration 
of r-HuEPO in patients treated with continuous ambulatory peritoneal dialysis 
(CAPD). During these studies it appeared that the acceptance of subcutaneous 
r-HuEPO varied drastically between two different pharmaceutical formulations of the 
hormone. Differences in local tolerance between the two brands were systematically 
assessed in haemodialysis patients. Studies to identify the pain-causing substance and 
to find measures to reduce pain with subcutaneous r-HuEPO were done in 
haemodialysis patients and in volunteers. Finally, since recommendations for treatment 
with r-HuEPO are still largely empirical, essential data were reviewed. 
The Use of Erythropoietin in Pre-Dialysis Patients 
Our first clinical trial in 24 pre-dialysis patients was designed as an open, 
randomised dose investigation. In the phase of correction of the anaemia fixed doses 
of 50, 100, or 150 U per kg of body weight (U/kg) were given intravenously three 
times a week for eight weeks. A continuous increase in haemoglobin was noted within 
two weeks of starting r-HuEPO treatment. The increase in haemoglobin was less in 
the 50 U/kg group than in both other dose groups. However, this intravenous dose 
seems to be appropriate to start treatment in most patients, thereby avoiding too rapid 
an increase of haemoglobin. During the maintenance phase intravenous r-HuEPO was 
administered once weekly, and patients were followed for at least six months. There 
was no loss of responsiveness and there were no toxic effects associated with 
protracted treatment. The mean dosages of r-HuEPO required to maintain a stable 
haemoglobin ranged between 35 to 325 U/kg per week. 
In a typical case the institution of r-HuEPO therapy is followed subsequently by an 
increase in reticulocyte counts, an increase in haemoglobin, and a decrease in serum 
ferritin values. However, when haemoglobin was increased slowly by low-dose 
r-HuEPO, significant changes in observed reticulocyte counts were absent, in spite of 
effective therapy. In patients using higher dosages increased reticulocyte counts rapidly 
returned to base-line values concurrent with dose reduction. The amount of iron 
required during r-HuEPO treatment depends mainly on the magnitude of new 
haemoglobin synthesis. A massive transfer of iron from storage sites is required 
during r-HuEPO therapy. In agreement with other investigators we noted a marked 
decrease in serum ferritin levels during the correction phase. The decrease also 
occurred when patients received oral iron supplementation from the start of the study. 
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During protracted iron supplementation serum ferritin values returned to values not 
significantly different from base-line values. In patients with renal failure, serum 
ferritin values less than 50 μg/L generally indicate a state of iron deficiency. Oral iron 
supplementation during several months partly corrected anaemia and significantly 
delayed the requirement for institution of r-HuEPO therapy in several of these 
patients. Adequate responses to r-HuEPO in spite of low serum ferritin values did 
occur during oral iron supplementation. This observation might indicate that the 
haemoglobin response can depend sometimes mainly on this source of iron. 
The most impressive benefit of effective r-HuEPO therapy was observed in 
significant subjective improvements in well-being, increased appetite, and increase in 
physical activity. In haemodialysis patients improvements in parameters of quality of 
life, cognitive function, sexual function, exercise tolerance, and reduction in exercise-
induced myocardial ischaemia and left ventricular mass have been established in 
objective tests. Although there is still a paucity of objective data on quality of life in 
pre-dialysis patients, there is no reason to assume that the benefit in pre-dialysis 
patients will differ from that in dialysis patients. 
In our study in pre-dialysis patients blood pressure was kept under control by 
institution or increase of antihypertensive medication. However, retrospectively we 
found that the mean blood pressure at the time of increase in antihypertensive 
medication did not differ significantly from base-line values. This might indicate that 
the prescribing behaviour with respect to antihypertensive medication may have been 
influenced by the increased frequency of blood pressure measurements in these 
patients and the awareness of reported severe hypertensive episodes during r-HuEPO 
treatment in haemodialysis patients. Nevertheless, the studies done so far indicate that 
blood pressure tends to rise during treatment with r-HuEPO, in particular during the 
initial phase of treatment as haematocrit is being corrected. This suggests that the 
increase in haematocrit is responsible for the changes in haemodynamics, potentially 
leading to elevated blood pressure. 
A more important point which merits special attention is the worrying expectation, 
based on data collected in animal experiments, that the increase in blood viscosity that 
accompanies the increase in haematocrit will cause glomerular hyperfiltration and 
glomerular hypertension, and subsequent acceleration of progressive renal failure. 
Micropuncture studies in rats showed that increased blood viscosity causes an increase 
of efferent renal arteriolar resistance which is proportionally larger when compared 
to changes in afferent arteriolar resistance. An increase of haematocrit in rats effected 
by isovolaemic exchange transfusions resulted in an increase in efferent renal arteriolar 
resistance, a marked increase in transcapillary hydraulic pressure gradient, and an 
increase in filtration fraction. In some experimental rat models this phenomenon of 
glomerular hyperfiltration, and also glomerular hypertension, was associated with 
mesangial proliferation, focal sclerosing lesions in the glomerulus, and progressive 
renal failure. In rats which had undergone five-sixth nephrectomy to induce renal 
failure it was shown that anaemia retarded the development of proteinuria and 
glomerular injury and reduced systemic hypertension. In contrast, treatment of the 
anaemia with r-HuEPO caused an acceleration of glomerular injury, and there was 
also a considerable rise in systemic blood pressure. This remnant kidney model is a 
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hypertensive model, in which systemic hypertension induces glomerular capillary 
hypertension, which is the major factor contributing to glomerular injury, 
hyperfiltration being much less important. In a normotensive remnant kidney model 
it was found that glomerular hyperfiltration was not accompanied by glomerular 
injury. In rat experiments in which r-HuEPO-induced hypertension was controlled with 
antihypertensive drugs, the rapid progression to end-stage renal failure that was seen 
in hypertensive control animals was effectively prevented. This suggests that the rapid 
progression of renal failure in this model is mainly related to the systemic 
hypertension that occurs after correction of the anaemia. 
It has been proposed that glomerular hyperfiltration and glomerular hypertension 
may also contribute to the progression of renal failure in patients with renal disease. 
Therefore, the observations in r-HuEPO-treated rats raised concern about the use of 
r-HuEPO in pre-dialysis patients. Direct measurements of glomerular intracapillary 
pressure cannot be obtained in humans. In the animal studies the increase of the 
glomerular transcapillary hydraulic pressure gradient is usually accompanied by an 
increase in filtration fraction (FF). Assuming that the filtration characteristics of the 
glomerular membrane (Kf) remain unaltered, changes in FF can be used in clinical 
studies as a parameter for changes in glomerular intracapillary pressure. Filtration 
fraction, as calculated from the ratio of glomerular filtration rate (GFR) and effective 
renal plasma flow (ERPF), varies directly with haematocrit in patients with 
polycythaemia. In one study with r-HuEPO-treated pre-dialysis patients a significant 
increase in FF was found concomitant with the increase in haematocrit. However, in 
these patients a significant increase in blood pressure occurred, which was left 
untreated. We studied renal haemodynamics in eight pre-dialysis patients treated with 
r-HuEPO. ERPF and GFR were measured by a standard clearance technique with 
continuous infusion of para-aminohippurate and inulin. In these patients blood pressure 
was monitored meticulously and antihypertensive medications were adjusted when 
necessary. Neither renal blood flow (RBF), nor GFR, nor FF had changed 
significantly at eight to 18 weeks after the start of r-HuEPO treatment, while 
haematocrits had increased substantially to low-normal or normal values. The values 
of ERPF tended to decrease, but the small changes in ERPF correlated well with the 
changes predicted from initial RBF and the change in haematocrit. Results from other 
studies have now confirmed the initial observations that acute deterioration of renal 
function does not occur during the correction phase of anaemia, when the haematocrit 
increases to almost normal values within a relatively short period of time, provided 
that blood pressure is kept under control carefully. 
It is more difficult to assess whether small increases in the progression of renal 
failure will occur during long-term treatment of anaemia with r-HuEPO. So far, only 
reports using changes in serum creatinine (SCr) as a parameter are available. 
Prospective studies including an appropriate control group of anaemic pre-dialysis 
patients not treated with r-HuEPO have not been done. Several investigators have 
observed that the reciprocal of SCr decreases linearly with time, suggesting that the rate 
of decline is related to the rate of decline in creatinine clearance (CCr). Since in 
individual patients a high correlation coefficient of the slope can be observed, the 
individual progression of renal failure can often be predicted, provided that 95 % 
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confidence intervals are taken into account. Serial measurements of SCr over a 
prolonged period of time in large numbers of patients are relatively reliable and cheap. 
Therefore, this method has been applied in most studies involving pre-dialysis patients 
by comparing slopes of the reciprocal serum creatinine values versus time before and 
during r-HuEPO therapy. We have collected data on 22 pre-dialysis patients who were 
included in two multicentre studies to assess the efficacy and safety of r-HuEPO 
treatment. The slopes encompassed periods of at least 10 months before and during 
r-HuEPO therapy. The mean slope improved significantly from —0.01917 before 
treatment to -0.01147 (1000/(μπιοΙ creatinine/L)/day) after correction of the 
haematocrit. Other investigators were also unable to detect significant negative changes 
in the slopes. Factors that could explain the improvement in the mean slope in our 
study include better dietary adherence and better blood pressure control. A simple 
'study effect' by more frequent check ups and better general patient care might also 
improve clinical outcome. On the basis of the current information it can be expected 
that the presumed detrimental effect of correction of the anaemia on renal function, 
if any, will not be very large. Obviously, long-term observations in large groups of 
patients are required to prove this point convincingly. It is clear that the benefits of 
treatment with r-HuEPO outweigh a probably small adverse effect on renal function. 
It remains of fundamental importance that blood pressure is carefully monitored and 
controlled during protracted r-HuEPO treatment. 
In the study of renal haemodynamics in our own patient group we have tried to 
answer another question that we thought relevant to the way in which hypertension 
should be treated in these patients. We reasoned that, on the basis of theoretical and 
experimental observations, angiotensin-converting-enzyme (ACE) inhibitors would be 
the best candidates for treatment of r-HuEPO-induced hypertension, since they also 
preferentially cause vasodilation of the efferent arterioles of the glomerulus and are 
thus best suited to prevent the presumed rise in glomerular intracapillary pressure. To 
test this hypothesis, we administered 25 mg of Captopril orally to eight pre-dialysis 
patients, who underwent measurements of ERPF and GFR before and after correction 
of their anaemia by r-HuEPO. Before correction of the anaemia, Captopril induced, 
as expected, a significant increase in ERPF, together with a decrease in mean arterial 
pressure and calculated renal vascular resistance (RVR). GFR remained unchanged 
and consequently FF also decreased. After correction of the haematocrit at eight 
weeks, base-line GFR, ERPF, RBF, and FF had not changed significantly. Also, the 
blood pressure lowering effects of Captopril had remained unchanged. By contrast, and 
somewhat unexpectedly, administration of Captopril no longer induced changes in 
ERPF or RVR. Since GFR also remained stable, FF did not change. 
The absence of an effect of Captopril on renal haemodynamics appeared to be 
sustained. Similar results were obtained when we repeated these renal function studies 
in four patients after a mean treatment period of 35 weeks. On the other hand, the 
renal response to Captopril reappeared in one patient whose haematocrit had fallen to 
the pre-treatment value. These results are highly suggestive for a mechanism of 
adaptive efferent renal vasodilation in pre-dialysis patients treated with r-HuEPO. 
Thus, changes in haematocrit may influence the effects of ACE inhibition on efferent 
vascular resistance. Results of several animal studies suggest that ACE inhibitors are 
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beneficial in reducing the rate of decline in GFR by their specific effect on efferent 
vascular resistance, irrespective of their blood pressure lowering effect. Our data 
suggest that treatment with Captopril for hypertension developing during r-HuEPO 
therapy does not seem to offer specific advantages over treatment with other 
antihypertensive drugs. Furthermore, the haematocrit should be taken into account 
when evaluating studies on the effects of ACE inhibition in the progression of chronic 
renal failure. 
Intraperitoneal and Subcutaneous r-HuEPO in CAPD Patients 
In our first studies it was proven that r-HuEPO is an effective treatment for the 
anaemia of chronic renal failure when given intravenously (IV) to pre-dialysis patients. 
However, Г administration of r-HuEPO, two or three times weekly, would be 
inconvenient in outpatients. Subcutaneous (SC) administration is established as the 
most convenient and cost-effective alternative. Yet, particularly in children, SC 
administration can cause considerable psychological distress. Therefore, we carried 
out a feasibility study to establish the efficacy and the clinical safety of multiple doses 
of r-HuEPO after intraperitoneal (IP) administration compared with subcutaneous 
administration, in patients with end-stage renal failure treated with CAPD. 
Intraperitoneal administration of other drugs, e.g. insulin in diabetes mellitus, is an 
accepted treatment modality. 
It is not known by which mechanism r-HuEPO (molecular weight 34 000 Dalton) 
is absorbed from the peritoneal cavity. However, it has recently been demonstrated 
that the disappearance of IP administered macromolecular solutes takes place mainly 
by lymphatic absorption. In CAPD patients lymphatic absorption rates of about 1.5 
mL/minute are found. Therefore, theoretically one would expect that the 
bioavailability of a fixed dose of IP r-HuEPO will increase with longer dwell times, 
and with lower intraperitoneal dialysate volumes. Indeed, in uraemic rabbits, 
absorption from the dry peritoneal cavity after 24 hours even reached 97 %. Thus, in 
the ideal situation IP r-HuEPO should be administered undiluted. However, since 
changes in the daytime dwell schedule are inconvenient in many outpatients, we 
preferred to reduce the overnight volume, containing 100 U/kg of r-HuEPO, to one 
litre three times a week in this pilot study. This did not interfere significantly with 
solute clearances as judged from unchanged clinical chemistry data. The results of the 
study showed that IP r-HuEPO is effective in correction of the anaemia, and results 
in subjective improvement in well-being. However, with the dwell schedule used, the 
rate of increase in haemoglobin was only half the rate in the SC treated group, 
receiving 100 U/kg thrice a week. Although SC r-HuEPO was superior to IP 
r-HuEPO, the results of this study show that IP r-HuEPO might be a convenient 
alternative when SC administration is undesirable. Further improvement of the IP 
efficacy might be achieved by reducing the volume in which r-HuEPO is administered. 
Pharmacokinetic studies of IP r-HuEPO showed that the mean bioavailability of IP 
r-HuEPO relative to IV administration, as measured by the area under the serum 
concentration curves, ranged from 3 % to 7 %. The mean relative bioavailability of 
SC r-HuEPO has been reported to range from 18 % to 49 %. These studies suggested 
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that SC and particularly IP r-HuEPO would not be effective treatment modalities. Yet, 
clinical studies demonstrated that SC r-HuEPO allowed for even lower dosages than 
IV r-HuEPO to obtain the same therapeutic effect. Therefore, it can be concluded that 
standard descriptive pharmacokinetics alone are not appropriate to predict the 
biological response to r-HuEPO. 
Increases in antihypertensive drugs prescribed, or institution of antihypertensive 
therapy in previously normotensive patients, occurred in both the SC and IP treated 
groups, independent of the rate of increase in haematocrit. The overall incidence of 
peritonitis during the study did not differ from the pre-treatment period in the IP 
treated group. Our experience suggests that with careful training the additional risk of 
peritonitis with IP administration of r-HuEPO is minimized, similar to the results with 
IP administration of insulin in С APD patients with diabetes mellitus. 
Interestingly, in three female patients a normal menstrual cycle resumed within one 
month after the start of IP r-HuEPO. This phenomenon might be explained by a 
decrease of hyperprolactinaemia caused by an increased haematocrit, as was seen in 
haemodialysis patients. Unfortunately, we did not measure prolactin levels. Similar 
observations were done in our pre-dialysis study. 
Local Tolerance of r-HuEPO Formulations after Subcutaneous Administration 
During studies in which r-HuEPO was administered subcutaneously, several patients 
reported unexpected pain at the injection site. Prior to r-HuEPO therapy the patients 
practised self-administration using normal saline, which was not painful. It was 
concluded that the r-HuEPO formulation itself caused pain. This side effect was 
limited to one of the r-HuEPO preparations (epoetin alpha) currently available. Since 
pain occasionally precluded long-term self-administration, we designed several studies 
to investigate the pain-causing factors and measures to reduce pain. Two validated 
pain scales were used by the patients and volunteers to assess pain after injections: a 
visual analogue scale (VAS) and a verbal descriptive scale (VDS). The studies were 
designed as double blind, placebo controlled, randomised order, crossover studies. 
Normal saline (0.9 %) served as a placebo control in all investigations. All injections 
were given by one experienced nurse. 
Epoetin alpha (Eprex, Cilag & Ortho Pharmaceuticals) and epoetin beta (Recormon, 
Boehringer Mannheim) are recombinant human erythropoietin products from two 
independent manufacturers, and do not show major differences. However, the two 
drugs differ in their formulation excipients. Epoetin alpha is diluted in an aqueous 
solution containing sodium chloride, citrate buffer, and human serum albumin. The 
latter two substances are not present in the epoetin beta solutions tested. 
The two r-HuEPO preparations were directly compared in haemodialysis patients 
regularly receiving SC r-HuEPO. It was shown incontestably that the formulation 
containing epoetin alpha was unique in causing pain after SC injection. Pain scores 
after SC injection of the epoetin beta preparation did not differ from those after 
injection of normal saline. All but one of 32 patients reported 'no pain' or 'very mild 
pain' on the VDS with epoetin beta, whereas these scores were obtained in only 10 
(31.3 %) patients after epoetin alpha. 
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In a subsequent similar study others found that the epoetin beta solution was 
significantly less painful than normal saline. It was suggested that this preparation 
might contain an anaesthetic substance. Therefore, although unlikely, a potential role 
of epoetin itself as a pain causing factor had not been ruled out. In haemodialysis 
patients the epoetin alpha preparation was compared with its vehicle, which was 
identical except that it did not contain epoetin. Both the epoetin alpha solution and its 
vehicle caused significantly and similarly more pain than normal saline in the patients 
studied. The percentage pain scores were similar to those found in the previous study. 
The results confirm the hypothesis that epoetin alpha itself does not contribute highly 
to the degree of pain after subcutaneous injection of its solvent. 
These results prompted us to analyse which of the component parts of the vehicle for 
epoetin alpha is responsible for pain experienced after SC injection. The vehicle was 
compared with a solution containing solely the citrate buffer and with another solution 
containing solely human serum albumin, their concentrations being identical to those 
in the vehicle. In volunteers the pain scores with the vehicle or its citrate component 
were similar and significantly higher when compared to normal saline or to the 
albumin component of the vehicle. Therefore, it can be concluded that the local pain 
experienced after subcutaneous administration of epoetin alpha preparations is mainly 
caused by the citrate component of the vehicle. 
The beneficial effects of r-HuEPO treatment are the main incentive for patient 
compliance during long-term self-administration. However, the therapy is not 
essentially vital and the drug does not exert acute effects. So, patient compliance 
during home use of epoetin is relatively more liable to be compromised. Strict 
adherence to the prescribed regimen is not easy to monitor. An important factor that 
influences patient compliance is the local tolerance of substances injected 
subcutaneously. When pain after SC injection of epoetin alpha occurs, it can be 
relieved easily by switching to another preparation. For those circumstances in which 
that change is not readily possible, alternative measures to reduce pain are necessary. 
Recently more concentrated solutions of epoetin alpha (10 000 U/mL) became widely 
available, and they do not differ from less concentrated solutions as regards the 
concentration of the citrate buffer. These solutions allow for the use of lower volumes 
to be injected. Therefore, we compared the effects of different volumes on pain 
experienced after subcutaneous injection of the vehicle for epoetin alpha. Volunteers 
experienced significantly less pain after injection of 0.1 mL of the vehicle when 
compared to 0.33 mL or 1 mL. Although the values obtained with 0.33 mL were 
intermediate to those of 1.0 and 0.1 mL, the difference with 1.0 mL was not 
statistically significant. Pain scores after 0.1 mL of the vehicle were still somewhat 
higher then after 1 mL of saline 0.9 %. These results suggest that the majority of 
patients can be treated without excess pain at the injection site by using low volumes 
of highly concentrated epoetin alpha solutions. 
One mL vials with concentrated solutions of epoetin must be suitable for multiple 
use to remain cost-effective. Preparations marketed in multiple-dose vials require the 
presence of a bacteriostatic agent. Therefore, we also investigated whether dilution of 
the vehicle for epoetin alpha with the commonly used bacteriostatic agent benzyl 
alcohol saline (BAS) had effects on pain, since BAS also has local anaesthetic 
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properties. We showed that dilution of the vehicle with appropriate amounts of a 
solution containing BAS, results in reduction of pain to levels comparable to those 
experienced with injection of normal saline. The resulting combined formulation 
contained BAS in a concentration that provides a lesser antimicrobial effect, and 
therefore is not expected to be suitable for multiple use. However, normal 
concentrations of BAS can be expected to be at least as effective. 
There are no reports on the effects of long-term subcutaneous administration of 
preparations containing citrate buffers. Citrate has been used as an anticoagulant in the 
extracorporeal circuit during haemodialysis. It has been reported to cause phlebitis and 
sclerosis after inadvertent intravenous infusion. The erythematous reaction seen in 
some patients suggests that the injection of epoetin alpha may cause a local 
inflammatory response. This raises the question of chronic inflammatory changes at 
the injection sites after long-term use. 
Recommendations for Therapy with r-HuEPO in Adults 
Symptoms of anaemia often occur when the haematocrit drops below 0.30 L/L 
(haemoglobin 6.0 mmol/L). This haematocrit value has been adopted as the essential 
criterion for institution of r-HuEPO treatment, unless other conditions such as angina 
pectoris or heart failure aggravated by anaemia, overt symptoms of anaemia, or the 
need for regular blood transfusions are present. When other possible causes of 
anaemia, other than erythropoietin deficiency, have been excluded, particularly 
deficiency of iron, folate, vitamin Bt2, and causes of blood loss, treatment with 
r-HuEPO should be considered in each patient with uncomplicated anaemia of chronic 
renal failure. When the haematocrit is between 0.25 and 0.30 L/L in patients who 
recently started dialysis, in particular CAPD, it usually makes sense to postpone 
r-HuEPO therapy three to six months. A small increase in haematocrit may occur 
during this period of time. 
Before and during treatment it is necessary to assess body iron stores, which is best 
achieved by the use of serum ferritin levels. Therefore, at the start and during the 
correction phase of r-HuEPO therapy, monitoring of serum ferritin should be done at 
monthly intervals, and every three months once the target haemoglobin is reached. In 
chronic renal failure absolute iron deficiency generally occurs when serum ferritin 
values are less than 50 Mg/L. Oral iron supplementation during several months before 
institution of r-HuEPO therapy may correct part of the anaemia in these patients. 
Patients with an initial ferritin level between 50 and 500 /zg/L ought to be on regular 
iron supplements (up to 200 mg of elemental iron per day) to avert iron deficiency, 
in particular during the correction phase of the anaemia. In the maintenance phase 
prolonged oral iron supplementation is required when serum ferritin levels are less 
than 100 to 250 μg/L, in order to maintain body iron balance. Sustained oral 
supplementation is effective in most patients. Values of mean corpuscular volume 
(MCV) of erythrocytes < 80 fL, transferrin values > 50 μπιοΙ/L, or transferrin 
saturation < 20 % may be indicative of functional iron deficiency in spite of normal 
or elevated ferritin levels. 
Treatment with r-HuEPO aims at correction of the anaemia until the target 
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haematocrit of maximum 0.35 L/L (haemoglobin 7.0 mmol/L) is reached. There is 
still no indication that higher values will be more beneficial with respect to subjective 
well-being or exercise tolerance. Moreover, it is not excluded that serious side effects 
will not occur more frequently at higher haematocrit. 
The published pharmacokinetic data of r-HuEPO do not provide a rational basis for 
its optimal prescribing schedule. Practical recommendations are empirical and are 
based on the results of therapeutic trials. Subcutaneous administration allows for using 
lower dosages than with intravenous usage, and is now widely accepted as the optimal 
route for r-HuEPO. Patients can be instructed easily to self-administer r-HuEPO in the 
way that is usual with insulin. The conventional SC starting dose is 25 U/kg three 
times weekly. In practice, a simplified, yet efficacious, schedule using a starting dose 
of 1000 or 2000 U three times weekly is in use, thereby avoiding drug wastage. In 
some patients dosing twice weekly can be acceptable during the maintenance phase. 
For those patients in whom IV dosing is required a starting dose of 50 U/kg (2000 to 
4000 U per dose) three times weekly is recommended. Less frequent IV dosing results 
in higher weekly dosages. 
In order to prevent too rapid a change in haematocrit the weekly dosages are 
adjusted in steps of 1000 U, or 12.5 to maximum 25 U/kg. This implies that the 
weekly dose often will be administered in three or two unequal portions. Since the 
current recommendations aim at a slow increase in haematocrit, absence of an 
adequate response can be assessed only four to six weeks after a dose increment. It 
should be kept in mind that the long-term 50 % and 90 % critical differences (intra-
individual variations) of haematocrit are 0.05 and 0.06 L/L. For haemoglobin these 
values are 0.9 and 1.4 mmol/L. Trends can only be diagnosed if serial values are 
examined. Usually, doses can be augmented when haematocrit increases less than 0.03 
L/L (haemoglobin less than 0.6 mmol/L) per four to six weeks. When haematocrit 
increases more than 0.05 L/L (haemoglobin 1 mmol/L) in four weeks or less, an 
immediate dose reduction is necessary. During the correction phase haematocrit should 
be monitored every one to two weeks. Once the target haematocrit is reached and 
sufficiently stabilized, continued monitoring of haematocrit can be done often at three 
to four weekly intervals. 
Inflammation, infection, severe osteitis fibrosa associated with hyperparathyroidism, 
aluminium intoxication, deficiencies of iron, folate, or vitamin B12, haemolysis, and 
blood losses may blunt the response to r-HuEPO. This may occur also during the 
maintenance phase of r-HuEPO therapy. Inflammation and iron deficiency are the 
most common causes of an inappropriate or declining response during r-HuEPO 
treatment. Acute inflammatory disorders and large surgical procedures often decrease 
the efficacy of r-HuEPO temporarily, until these states have resolved. Increasing the 
dosage of r-HuEPO is generally ineffective, but r-HuEPO should not be withheld. 
Increase in blood pressure usually occurs during the correction phase of the anaemia 
and is less of a problem during the maintenance phase. Hypertension can occur also 
in previously normotensive patients. Careful monitoring and prompt adjustments of 
the antihypertensive regimen when blood pressure rises are indicated. A gradual 
increase in haematocrit to target levels at or below the lower limit of normal should 
prevent most serious hypertensive problems. 
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Klinische studies met 
recombinant-humaan erytropoëtine 
bij chronische nierinsufficiëntie 
Samenvatting 

Samenvatting 
De aanmaak van erythrocyten door het beenmerg wordt voornamelijk geregeld door 
middel van het hormoon erytropoëtine (EPO). De produktie van EPO vindt nagenoeg 
volledig plaats in de nieren. Hierdoor vervullen de nieren, naast hun functie als 
uitscheidingsorgaan, een belangrijke taak voor de zuurstofvoorziening van de weefsels. 
Gestoorde nierfunctie gaat meestal gepaard met onvoldoende produktie van EPO. Dit 
is de belangrijkste oorzaak van anemie bij patiënten met nierinsufficiëntie. Anemie is 
een veel voorkomende complicatie van nierinsufficiëntie en leidt bij de meeste 
patiënten tot een verminderde inspanningstolerantie, chronische moeheid en 
verminderde kwaliteit van leven. 
Tot voor kort kon ernstige anemie veroorzaakt door nierinsufficiëntie alleen behandeld 
worden door bloedtransfusie. Herhaalde toediening van bloed kan aanleiding geven tot 
ongewenste bijwerkingen. In tegenstelling tot bijvoorbeeld insuline kon het tekort aan 
EPO niet vervangen worden met injecties omdat bereiding van menselijk EPO uit 
natuurlijke bronnen te geringe hoeveelheden opleverde. Echter, nieuwe technische 
ontwikkelingen in de biologie hebben geleid tot de fabriekmatige produktie van grote 
hoeveelheden recombinant-humaan erytropoëtine (r-HuEPO, epoetin). R-HuEPO is 
identiek aan het natuurlijke EPO dat door de nieren wordt gemaakt. De komst van 
r-HuEPO leidde tot een volkomen nieuwe mogelijkheid voor behandeling van anemie 
bij nierpatiënten. 
De eerste studies met r-HuEPO werden verricht bij anemische patiënten met terminale 
nierinsufficiëntie die werden behandeld met hemodialyse. De door nierinsufficiëntie 
veroorzaakte anemie kon door behandeling met r-HuEPO volledig gecorrigeerd 
worden. Het effect van r-HuEPO op de erytropoëse was afhankelijk van de 
toegediende hoeveelheid. Tijdens de correctie van anemie door r-HuEPO verbetert de 
zuurstofvoorziening van de weefsels. Hiermee samenhangend zijn belangrijke 
verbeteringen van het welbevinden en inspanningstolerantie vastgesteld. Veel algemene 
verschijnselen zoals moeheid, last van koude, verminderde eetlust, emotionele 
labiliteit, concentratiestoornissen en libidoverlies verbeteren eveneens. Herhaalde 
transfusies met de daaraan verbonden risico's kunnen door het gebruik van r-HuEPO 
vermeden worden. Het uitbannen van transfusies zal ook de vorming van HLA-
antistoffen, die het vinden van een geschikte donornier voor patiënten met 
nierinsufficiëntie ernstig kunnen bemoeilijken, in de toekomst tot een kleiner probleem 
maken. 
Wij onderzochten de werkzaamheid en veiligheid van behandeling met r-HuEPO bij 
anemische patiënten met chronische nierinsufficiëntie die nog niet behandeld werden 
met dialyse (hoofdstuk 1). In de fase van correctie van de anemie werd r-HuEPO bij 
deze pre-dialysepatiënten drie maal per week intraveneus toegediend, daarna één maal 
per week. Bij alle patiënten kon de anemie volledig gecorrigeerd worden. Een 
begindosis van 50 eenheden r-HuEPO per kilogram lichaamsgewicht (E/kg) was in de 
regel voldoende. Een snelle stijging van de hematocriet, zoals werd gezien bij hogere 
doses, werd hiermee voorkomen. Alle patiënten meldden een belangrijke verbetering 
van hun welbevinden en inspanningstolerantie. De behandeling had geen klinisch 
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belangrijke bijwerkingen. Met name waren er geen aanwijzingen voor een versnelde 
achteruitgang van nierfunctie. 
Theoretische overwegingen en resultaten van dierexperimenteel onderzoek 
suggereerden dat de toename van hematocriet de nierfunctie zou kunnen beïnvloeden. 
Specifieke onderzoekingen van merfunctie en renale hemodynamiek tijdens 
behandeling met r-HuEPO bij pre-dialyse patiënten hadden daarom onze bijzondere 
aandacht (hoofdstuk 2). Ook bij deze nauwkeurige onderzoekingen van de nierfunctie 
werd geen nadelige invloed van behandeling met r-HuEPO op de progressie van 
nierinsufficièntie vastgesteld. Toediening van het antihypertensivum Captopril, een 
remmer van het angiotensine-converterend enzym, resulteerde tijdens anemie in een 
afname van de efferente vaatweerstand in de nier. Na correctie van de anemie trad dit 
verschijnsel niet meer op. Wanneer opnieuw anemie ontstond was dit effect wederom 
meetbaar. Deze renale hemodynamische studies wijzen op adaptieve veranderingen in 
het vaatbed van de nier tijdens anemie of correctie ervan. Bij de behandeling van 
hypertensie bij genormaliseerde hematocriet bieden de specifieke effecten van Captopril 
op de efferente renale vaatweerstand waarschijnlijk geen bijzondere voordelen in 
vergelijking met andere antihypertensiva. 
Hypertensie is een belangrijke potentiële bijwerking van behandeling met r-HuEPO. 
In hoofdstuk 3 worden verschillende factoren besproken die samenhangen met het 
ontstaan hiervan. Hemodynamische veranderingen zijn het gevolg van de toename in 
hematocriet. Op welke wijze deze aanleiding geven tot het ontstaan of verergeren van 
hypertensie is nog niet geheel opgehelderd. Het is wenselijk om de hematocriet 
langzaam te laten stijgen door de behandeling met lage doses te beginnen. Hierdoor 
kan mogelijk voorkomen worden dat de noodzakelijke hemodynamische aanpassingen 
niet tijdig plaatsvinden. Eveneens kan dan bij een eventuele bloeddrukverhoging tijdig 
de antihypertensieve behandeling worden aangepast. Nauwgezette controle van de 
bloeddruk is een absolute voorwaarde voor behandeling met r-HuEPO. Hypertensie 
is een belangrijke oorzaak van versnelde progressie van nierinsufficièntie. Verhoging 
van de hematocriet zonder meer heeft geen aantoonbare belangrijke nadelen voor de 
nierfunctie. Nauwkeurige onderzoekingen zijn echter nog niet op grote schaal verricht. 
In de eerste studies werd r-HuEPO intraveneus toegediend. Voor poliklinische 
behandeling is deze toedieningswijze onpraktisch. Bij patiënten met chronische 
nierinsufficièntie die behandeld werden met continue ambulante peritoneale dialyse 
(CAPD) onderzochten wij daarom de werkzaamheid en veiligheid van intraperitoneale 
en subcutane toediening van r-HuEPO (hoofdstuk 4). R-HuEPO werd drie maal per 
week toegediend. Intraperitoneale toediening gebeurde in een dialysaatvolume van één 
liter gedurende de nacht. Beide toedieningswijzen waren effectief. Subcutane 
toediening was echter superieur aan intraperitoneale toediening, zoals bleek uit de 
snellere stijging van de hematocriet en de lagere onderhoudsdoses. Het effect van 
intraperitoneaal toegediend r-HuEPO lijkt afhankelijk van de concentratie van 
r-HuEPO in de dialysevloeistof en van de intraperitoneale verblijftijd. Intraperitoneale 
toediening van r-HuEPO in een klein volume kan de effectiviteit doen toenemen. 
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Vooral voor kinderen die behandeld worden met peritoneale dialyse kan 
intraperitoneale toediening van r-HuEPO een bruikbaar alternatief zijn. Verhoging van 
bloeddruk tijdens correctie van de anemie kwam ook bij deze toedieningsvormen voor. 
Belangrijke bijwerkingen werden niet waargenomen. Met name was er geen toename 
van de incidentie van peritonitis bij intraperitoneale toediening. De werkzaamheid van 
subcutane en intraperitoneale toediening was veel hoger dan op grond van 
literatuurgegevens over de biologische beschikbaarheid in vergelijking met 
intraveneuze toediening verwacht was. Onze resultaten tonen aan dat standaard 
beschrijvende farmacokinetiek alléén niet voldoende is om de biologische 
werkzaamheid van r-HuEPO te voorspellen. 
Epoetin alfa (Eprex®) en epoetin beta (Recormon®) zijn r-HuEPO-produkten afkomstig 
van twee verschillende fabrikanten. Zij verschillen niet in klinische werkzaamheid. De 
farmaceutische samenstelling van het oplosmiddel van deze preparaten is wezenlijk 
anders. In hoofdstuk 5 wordt aangetoond dat Eprex bij subcutane toediening vaak 
lokaal pijn veroorzaakt. Recormon verschilde niet van fysiologisch zout dat als placebo 
en controle werd gebruikt. 
Het vehiculum van Eprex is een oplossing van humaan serum albumine en een 
citraatbuffer in fysiologisch zout. Wij vergeleken de lokale pijnlijkheid van het 
vehiculum en van Eprex met die van fysiologisch zout (hoofdstuk 6). Het vehiculum 
veroorzaakte in dezelfde mate lokale pijn als Eprex. Het was bijgevolg aannemelijk 
dat een van de samenstellende bestanddelen van het vehiculum, en niet epoetin alfa 
zelf, de oorzaak was van pijn bij subcutane toediening. In hetzelfde hoofdstuk wordt 
aangetoond dat de citraatbuffer in het vehiculum van Eprex deze pijn veroorzaakt. 
Albumine speelde geen rol bij deze bijwerking. 
De door Eprex veroorzaakte pijn verhinderde soms subcutane toediening door de 
patiënt zelf. Daarom onderzochten wij enkele potentiële maatregelen om deze pijn te 
verminderen (hoofdstuk 7). Vermindering van het ingespoten volume van het 
vehiculum tot 0,1 mL reduceerde de pijnlijkheid tot vrijwel de lage graad die werd 
waargenomen bij toediening van fysiologisch zout. Meer geconcentreerde oplossingen 
van epoetin alfa bevatten gelijke concentraties citraatbuffer als andere oplossingen. 
Door subcutane toediening van een gering volume van hoog geconcentreerde 
oplossingen van epoetin alfa kunnen de meeste patiënten zonder onnodige pijn worden 
behandeld. Bij subcutane toediening is de benodigde dosis r-HuEPO in de regel laag. 
Kleine volumes geconcentreerd r-HuEPO voor eenmalige toediening zijn nog niet 
beschikbaar. Om de inhoud van de gebruikelijke ampullen langer houdbaar te maken 
voor meermalige toediening uit één ampul wordt gezocht naar geschikte 
conserveringsmiddelen. Het bacteriostatische middel benzylalcohol is één van de 
kandidaten hiervoor. Benzylalcohol heeft ook lokaal-anesthetische eigenschappen. In 
hetzelfde hoofdstuk wordt beschreven dat toevoeging van benzylalcohol aan het 
vehiculum van Eprex de pijn bij subcutane toediening volledig elimineerde. 
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De snelle en enthousiaste klinische introductie van г-HuEPO als een bewezen 
effectieve behandeling voor anemie veroorzaakt door chronische nierinsufficiëntie ging 
vooraf aan meer fundamenteel klinisch onderzoek. Over de farmacodynamiek van 
г-HuEPO is nog weinig bekend. De farmacokinetische gegevens over r-HuEPO 
vormen geen rationele basis voor gewenste therapeutische bloedspiegels of 
farmacokinetische profielen. De aanbevelingen voor behandeling met r-HuEPO zijn 
daarom grotendeels empirisch. Hoofdstuk 8 geeft een overzicht van achtergronden en 
algemeen aanvaardde richtlijnen voor substitutietherapie met r-HuEPO. 
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